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Abstract
A considerable body of evidence from molecular, cytogenetic and functional studies 
points to the existence of a novel tumour suppressor gene on the long arm of human 
chromosome 7. This putative gene seems to be conserved between mouse and man, 
since a high frequency of allele loss is evident at mouse chromosome 6 band A2, the 
region syntenic to human chromosome 7q31, in the two-stage skin carcinogenesis 
system. In addition, introduction of human chromosome 7 into mouse tumour cell lines 
results in increased latency in tumorogenic assays, implying functional conservation. To 
date, this gene has not been isolated.
I undertook loss of heterozygosity studies in a series of mouse skin tumours produced 
by the two-stage carcinogenesis protocol. After saturating the area of interest on mouse 
chromosome 6A2 with all available published microsatellite markers, I defined a 
possible smallest common deleted region between the markers D6mit83 and D6mit50. 
Allelotyping analysis of a panel of mouse cell lines representative of the sequential 
stages in skin carcinogenesis demonstrated allelic imbalance of markers on chromosome 
6. FISH analysis of a selection of these cell lines using whole chromosome paints 
confirmed aneuploidy with tri- or tertrasomy of chromosome 6 being common. The 
finding of trisomy of chromosome 6 was seen in both papilloma and carcinoma cell 
lines, suggesting that this is an early event in skin carcinogenesis.
Concurrent work in our laboratory on human chromosome 7 has generated a number of 
candidate tumour suppressor genes which map to chromosome 7q. Full-length cDNAs 
corresponding to three of these genes were cloned from a mouse foetal cDNA library, 
and analysed for mutational inactivation in the panel of mouse tumour cell lines. No 
mutations were evident. One of these genes was a novel homologue of kelch, an actin 
binding molecule first identified in Drosophila. This proved to possess both POZ and 
kelch repeat domains, commonly seen in the kelch family of genes, and showed a high 
degree of similarity to the human kelch homologue.
xiv
CHAPTER 1 
INTRODUCTION
1
1. Introduction
1.1 Tumour Suppressor Genes and the Genetics of Cancer
Like much of biology, our understanding of cancer has undergone wholesale 
revision following the advent of the techniques of molecular biology in the 1970s. 
Prior to that time, tumour development was very much a black box, variously 
ascribed to viral infection, defective immunity and, nebulously, ‘genetic alteration’. 
The unifying picture to emerge over the last two or three decades is that, put 
succinctly, cancer is a genetic disease of cells. Much of the research on 
carcinogenesis has focused on identification of those genes which, when altered, 
lead to the development of cancers. It has become clear that there is a finite number 
of commonly altered genes, whose normal role is as part of the signal transduction, 
cell cycle, cell differentiation and genome maintenance machinery. These genes are 
classifiable broadly as oncogenes or positive regulators of cell growth, and tumour 
suppressor genes (TSGs) or negative regulators. Epidemiological and other data 
point to there being a requirement for at least four or five genetic changes before 
development of the malignant phenotype. The emerging theory is that tumorigenesis 
is a multistage process requiring serial alterations in oncogenes and TSGs before the 
clinically recognised syndrome of cancer is seen. The sequence of these genetic 
changes is now becoming clear and is opening the way to novel therapeutic 
interventions.
1.1.1 Oncogenes
Oncogenes are genes which undergo ‘gain of function’ alterations in cancer cells. 
The study of oncogenes began with experiments on the Rous sarcoma virus (RSV), 
one of the acutely transforming retroviruses (reviewed in Weiss, 1984). These 
viruses were shown to possess, in addition to their normal genomic content, 
extraneous DNA sequences which were responsible for acute oncogenesis. In fact, 
RSV is unique in having all genes necessary for viral replication (gag, pol and env)
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in addition to the oncogenic v-src; all other acute retroviruses lack one of the 
structural genes, rendering them replication incompetent. The entirely unexpected 
finding that the oncogenic DNA sequences hybridised to normal cellular DNA from 
a variety of vertebrates (Stehelin et ah, 1976) ushered in a new era in molecular 
oncology. Such proto-oncogenes transpired to be genes whose protein products have 
crucial roles to play in controlling the proliferation of normal cells. Their presence in 
viral RNA is thought to result from the process of transcription of proviral DNA, 
when they are ‘captured’ or transduced from the host genome (Bishop, 1982). In all, 
some twenty oncogenes were discovered in this fashion. Viral oncogenes have 
commonly undergone mutation in their coding region which alters the biochemical 
properties of the gene product. Others, however, harbour no detectable alterations 
and are oncogenic by virtue of the fact that they are under the transcriptional control 
of the constitutively active viral long terminal repeats. Indeed, retroviruses causing 
cancer after long incubation periods possess no oncogenes: they produce their 
oncogenic effect by proviral integration into or near host cellular proto-oncogenes 
(Hayward et a l, 1981).
There are in fact a number of mechanisms whereby proto-oncogenes can be 
activated aberrantly within normal cells, resulting in transformation. Cytogenetic 
alterations have long been associated with cancer cells, and were suspected to be 
causal of, or at least contributory to, the malignant phenotype. Translocations of the 
myc and Ig genes have been observed in B cell derived tumours in man and rodent 
species. In Burkitt’s lymphoma and the B-cell leukaemias, the principle alteration is 
a juxtaposition of the myc oncogene and the Ig  heavy chain gene (Leder et al., 
1983). By this mechanism, the myc oncogene is constitutively expressed, resulting in 
cellular transformation. Another means by which the action of proto-oncogenes can 
be altered is by the formation of fusion proteins. This is precisely the alteration 
occurring in the long recognised Philadelphia chromosome found in the vast 
majority of patients with chronic myeloid leukaemia (CML) and in a smaller 
proportion of those with ALL. Here, the classical translocation is between the long 
arms of chromosomes 9 and 22 (t(9;22)(q34;qll)), resulting in the fusion of the abl
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proto-oncogene on chromosome 9 with the bcr gene on chromosome 22 and 
ultimately in a chimeric protein with constitutive tyrosine kinase activity 
(Heisterkamp et al, 1982). In over 90% of CML, bcr sequence is juxtaposed to exon 
2 of abl, forming a 210kDa fusion protein, p210. That the bcr-abl protein is indeed 
oncogenic and causative of the disease can be proved by transgenic studies in mice: 
forced expression of the protein in haemopietic progenitor cells in mice results in a 
CGL-like syndrome (Elefanty et al., 1990; Gishizky et al., 1993).
Gene amplification is often visible cytogenetically as episomal double minute (DM) 
chromosomes (Schwab et al., 1983), or as chromosomally integrated homologously 
staining regions (HSRs) (Alitalo et al., 1983), and can again result in oncogenic 
activation by a gene dosage effect. Although long stretches (up to 2 megabases) of 
DNA can be so altered, sometimes making it uncertain which precise genes are 
involved, the majority of amplifications seen in human cancer involve the myc 
family of oncogenes, the ras family, and growth factor receptors such as erbB-1 and 
-2. In small cell lung cancer, for example, all three members of the myc family are 
amplified with moderate frequency, whereas it is N-myc that is preferentially 
amplified in neuroblastoma cells (Schwab, 1993). These changes presumably confer 
some growth advantage, since they are not observed in normal cells. Many studies 
have attempted to correlate the presence of gene amplication with clinical outcome. 
The evidence would suggest that gene amplication is associated with a more 
invasive phenotype and thus a poorer prognosis. In the case of breast cancer, there 
has been huge interest in the presence of erbB-2 overexpression, as detected by in 
situ hybridisation or immunocytochemistry, and its correlation with ER negative 
cancers and poor prognosis (Slamon et al., 1987). The introduction of trastuzumab, a 
humanised monoclonal antibody against the extracellular domain of erbB-2 (Carter 
et al., 1992), as a therapy in metastatic breast cancer has refocused attention on the 
subject and may soon make erbB-2 status as common a test and as relevant to 
treatment as ER status.
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The extensive conservation of proto-oncogenes across all multicellular organisms 
points to a crucial biological role for these molecules. Invariably they form part of 
the signal transduction pathway relaying mitogenic signals from the cell surface to 
the nucleus. There are probably only three biochemical modes of action of 
oncogenes: phosphorylation of nascent proteins on tyrosine, serine or threonine 
residues; abnormal molecular switching by GTPases; and abnormal transcriptional 
activation by nuclear oncogenes. A classification of oncogenes and their cellular 
localisation is given in table 1.1. The cellular tyrosine kinases, both transmembrane 
and cytoplasmic, regulate key events controlling cell growth and morphology, and 
aberrant activation of these renders the cell mitogen-independent. In the case of 
membrane-associated tyrosine kinases, mutations that promote ligand independent 
dimerisation and subsequent kinase activity are seen as representing a general 
mechanism of activation for this class of oncogene. Similarly, non-receptor tyrosine 
kinases assume constitutive kinase activity after mutation, which activates 
downstream signalling molecules. The discovery of ras, the archetypal GTPase, and 
elucidation of its role as a binary switch (McCormick, 1989) was a crucial landmark 
in signal transduction research. The ras family (N- H- and K-ras) is one of the 
commonest class of oncogenes to undergo mutational activation in human cancer. In 
the GTP-bound state, ras activates complex signal transduction cascades including 
Raf and MAP kinase, which ultimately converge on nuclear oncogenes such as myc 
and jun. The nuclear protein family is implicated directly in the activation of gene 
expression (Lewin, 1991), and the majority have been shown to possess trans- 
activating activity. Figure 1.1 serves to give an overview of the role proto-oncogenes 
play in conducting mitogenic signals from cell surface to nucleus.
1.1.2 Tumour Suppressor Genes
One definition of a tumour suppressor gene, which relates historically to their mode 
of discovery, is any gene that is capable of suppression the malignant phenotype in 
in vitro assays or in vivo tumour models. In contradistinction to the oncogenes,
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Table 1.1 A classification of oncogene
Growth Factors
FGF5, INT2, HST1, SHH, SIS/PDGFB, WNT1, WNT3
Growth Factor Receptors: Tyrosine Kinases
EPH, ERB-B/EGFR, FMS, KIT, MET, NEU/HER2/ERB-B-2, RET, ROS, SEA, 
TRK
Non-receptor Tyrosine Kinases
membrane-associated:
SRC, FGR, FYN, HCK, LCK, LYN, TKL, YES
cytoplasmic:
ABL, FPS/FES
Cytoplasmic Regulators of Protein Activity
SH2/SH3 containing adaptors:
CRK, NCK, SHC
guanine nucleotide exchange factors:
DBL, ECT2, LBC, TIAM1, VAV
other:
CBL
Membrane-associated G Proteins
HRAS, KRAS2, NRAS, GSP, GIP2
Cytoplasmic Protein Serine/Threonine Kinases
AKT, BCR, MEK1/2, MOS, PIM1, RAF/MIL, TPL2
DNA-binding Nuclear Proteins (transcription factors)
ALL1/MLL, ERB-A/THRA, ETS1, ETS2, FOS, JUN, MYC, MYB, REL, TALI, 
SKI
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which act dominantly, TSGs are recessive at the cellular level, requiring deletion of 
both alleles before contributing to oncogenesis. As a direct consequence of being 
recessive, their identification has proved more demanding than has been the case 
with oncogenes since assays to detect non-transformed revertants in the context of 
proliferating, transformed cells are technically fraught. Nonetheless, about a dozen 
or so TSGs have now been identified and characterised. Their function is typically 
as regulators or impeders of cell cycle progression, or as promoters of 
differentiation.
The story of TSGs begins with observations made by Harris and colleagues (1969, 
1988) that growth of murine cancer cells could be suppressed by fusion with non- 
tumorigenic cells. Such somatic cell hybrids tended to revert to the malignant 
phenotype over time, an event that coincided with the loss of chromosomes from the 
cell. It was soon observed that reversion was linked to loss of particular 
chromosomes, and not chromosome loss in itself. Together these observations 
supported the view that malignancy was a recessive trait, and that a particular 
chromosome or a small number of genes might be responsible for the tumour 
suppression. It required the advent of microcell medicated chromosome transfer 
techniques to test this hypothesis properly. Using this technique (figure 1.2), 
introduction of a tagged chromosome (Koi et al., 1989) or subchromosomal region 
(Sanchez et al., 1996) into a transformed cell can be accomplished.
Almost concurrently with these experiments, Knudson was conducting 
epidemiological investigations into the childhood cancer retinoblastoma (Knudson, 
1971). Although usually a sporadic disease, it was recognised that retinoblastoma 
occurred in families, and that in these conditions bilateral disease was more 
prevalent. Such families also tended to develop the malignancy earlier compared to 
the sporadic form. Based only on a statistical analysis of his observations, Knudson 
framed one of the most influential ideas in the history of cancer genetics, the ‘two 
hit’ hypothesis. Here, he proposed that two events or mutations were necessary to 
the formation of retinoblastoma. In familial disease, the first mutation was present in
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the germ line of the patient and therefore in all somatic cells. One inactivating event 
was not, however, enough to result in disease, only to confer susceptibility. A 
second event was required and occurred by somatic mutation. Since the occurrence 
of two mutations is an unlikely event, the chance of sporadic cases developing 
bilateral disease is correspondingly low. Sporadic cases would also be expected to 
manifest later as is indeed the case. Experimental confirmation of Knudson’s 
hypothesis came with cytogenetic and molecular studies of retinoblastoma cases 
(Cavenee et al., 1983, 1985). A proportion of patients harbour a deletion in 
chromosome 13, providing the first mapping data for the retinoblastoms gene, RBI. 
The second ‘hit’ occurs as a microdeletion event, detectable by LOH analysis. A 
more detailed discussion of the techniques used to map and clone candidate tumour 
suppression genes follows.
Since its cloning in 1987 (Lee et al., 1987), the retinoblastoma gene and its protein 
product (pRB) has become the focus of intense research. In many respects, it takes 
centre stage in the study of tumorigenesis since it functions as a key regulator of cell 
cycle progression. Arguably, it is the TSG about which most is known. Its 
importance was first hinted at when it became clear that transforming proteins 
derived from DNA tumour viruses (including adenovirus E1A and papillomavirus 
E7) bind to and inactivate Rb (Whyte et al., 1988; Dyson et al., 1989). It has since 
been suggested that the majority of (or perhaps all) cancer cells possess defects in 
this pathway, either upstream or downstream of pRB. To understand the importance 
of pRB it is necessary to understand more fully cell cycle biology.
In normal, physiological conditions, a cell is recruited into the cell cycle only when 
expansion of cell numbers is required, and this is effected by the balance of mitotic 
and antimitotic signals converging on the cell cycle regulatory machinery. 
Traditionally, the cell cycle has been divided into four phases (figure 1.3): S phase, 
DNA replication or synthesis; M phase, mitosis; and G1 and G2, gap phases when 
the cell is metabolically active and preparing for DNA replication and mitosis, 
respectively. Our understanding of the sequence of molecular events derives
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primarily from work with yeast. Yeast genetics are such that it is easy to identify 
genes whose mutation results in impaired progression from one phase of the cell 
cycle to the next, and the seminal work of Hartwell and colleagues identified a 
number of genes whose products are obligatory to the progression of the cell cycle 
(reviewed in Hartwell, 1991). These proteins are known today as the cyclins and 
cyclin dependant kinases (cdks). Although identified in yeast, these molecules are 
remarkably well conserved in all eukaryote organisms. In man the situation is more 
complex, but the principle holds true: activity of certain cdks is specific to certain 
parts of the cell cycle which themselves require interaction with cyclins before 
becoming active kinases. It follows that the abundance of cyclins, which were again 
originally discovered through homology with yeast proteins, is extremely tightly 
regulated, both at the transcriptional level and by proteolytic degradation. Figure 1.3 
demonstrates the pattern of cyclin-cdk activity at different phases of the cell cycle. 
As can be seen, a crucial watershed from the point of view of the cell is its
CyclinB-cdc2
CyclinA-cdc2 Growth
/factors
► GO
Antimitogens 
'TGF0, p53, Rb
G2 START or R 
point
G1
Cyclin D-CDK4 and 
CDK6
Cyclin E and CDK2
Cyclin A and CDK2
CyclinE-CDK2
Figure 1.3 A simplified view of the cell cycle. See text for description.
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(irreversible) commitment to a round of DNA synthesis and division. This control 
point is very clearly demarcated in yeast and is termed START (Cross, 1995). 
Although less purely defined, the corresponding decision for human cells is termed 
the R, or restriction, point (see Zetterberg et al., 1995 for overview). It should be no 
surprise that this is the point at which the greatest number of signalling pathways 
converge and at which the control mechanisms are at their most stringent. The 
predominant G1 cyclin is the D-type cyclin group, whose specific role has been 
defined as the chief regulator of Rb. This it does through influencing Rb’s 
phosphorylation status: hypophosphorylated pRb is capable of binding and 
sequestering large numbers of proteins such as E2F, a crucial transcription factor, 
whereas in the hyperphsphorylated state, E2F is released and able to function. In 
support of this, viral oncoproteins target only the hypophosphorylated form of pRB, 
thus permitting uncontrolled viral replication. Mutation or chromosomal deletion of 
pRB is moderately common in a range of cancer types, but alterations in upstream 
regulatory proteins are arguably more so. The cyclinD-cdk4 complex inactivates 
pRB thereby releasing E2F, and both these genes are mutated in a range of epithelial 
cancers. p l5  and p l6  both cdk inhibitors of the INK4 family, are also found to be 
altered not infrequently in tumour cell lines derived from common cancers such as 
lung, oesophagus and bladder (Kamb et al., 1994; Nobori et al., 1994). A number of 
pRB like proteins have now been described (Ewen et al., 1991; Li et al., 1993), and 
different proteins appear to bind different members of the E2F group of transcription 
factors. To date, however, no mutations have been identified in these related 
proteins, implying a distinct physiological role for pRB. Other targets for pRB are 
known, c-abl is ubiquitously expressed and has been shown to interact with pRB 
(Welch et al., 1993). Its action may well be important in cell cycle regulation.
If pRb is the prototypical TSG, then p53 has the distinction of being the most 
commonly mutated gene across the spectrum of human cancers. Originally thought 
to be an oncogene by virtue of its initial isolation in association with the SV40 large 
T antigen (Lane and Crawford, 1979), subsequent work showed that the wild type 
(wt) protein functions as a classical TSG. Reintroduction of wt p53 into p53
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deficient cells results in growth inhibition; cells exhibit growth arrest at or near the 
Gl/S phase transition. A further observation, made early in p53 research, is that 
exposure of cells to UV light, or other genotoxic agents, leads to accumulation of 
p53 and delayed cell cycle progression (Maltzman et al., 1984; Kastan et al., 1991). 
This response is particularly dramatic in response to double stranded DNA breaks, 
as might be produced by ionising radiation or alkylating agents. The evidence from 
numerous experiments is compelling that p53 plays an important part in the cellular 
response to DNA damage. The current model is that p53, when activated, causes the 
cell to pause in G1 (and G2) while initiation of DNA damage repair takes place, thus 
maintaining the integrity of the genome (Shimamura and Fisher, 1996). The 
molecular events whereby p53 acts have begun to be unraveled. p53 protein itself 
acts as a transcription factor with a number of downstream targets. Both GADD45 
and p21 are upregulated in response to p53 (Kastan et al., 1992; El-Deiry et al.,
1994), and both proteins result in growth inhibition. p21 acts directly to inhibit the 
G1 associated cdks, and is seen as a crucial downstream target of p53. Transfection 
studies also demonstrate that p53 can lead to programmed cell death, or apoptosis, 
which it does through transcriptional control of box and bcl2 (Miyashita et al.,
1995). Although there appears to be a further, /?55-independent pathway for 
apoptosis, an appealing proposal which has gained wide currency is that p53 leads to 
the apoptotic destruction of cells which cannot be repaired following DNA damage. 
For these reasons, p53 has earned the epithet ‘guardian of the genome’ (Lane, 1992).
To date, the majority of Mendelian cancer dispositions have been found to have as 
their aetiology a germline mutation in a TSG, with the exception of MEN2 where 
the ret proto-oncogene is altered (Ponder, 1995). This has been a crucial means of 
discovery of novel TSGs. The converse is, of course, not necessarily true. There may 
well be many TSGs not associated with heritable germline mutations and consequent 
cancer family syndromes. In addition to family linkage analysis, and as implied by 
the two hit model of Knudsen, a search for LOH is a common means of ‘fishing’ for 
tumour suppressors. Indeed, there are many chromosomal sites with moderate to 
high (20%+) levels of LOH where no novel TSG has yet been isolated. One such
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site is the long arm of human chromosome 7 (reviewed in Zenklusen and Conti, 
1996a) and the syntenic region of mouse, 6A2. It is the linkage method and the 
occasionally observed cytogenetic changes that have been most fruitful in 
identifying TSGs: WT1, BRCA1 and 2, APC, NF1, VHL, BLM and others (see 
table 1.2) were identified in this fashion. There remain several dozen cancer family 
syndromes where no germline mutation has as yet been discovered. These might in 
time be expected to yield information on novel TSGs.
Identification of the BRCA genes was the culmination of several years’ work by a 
number of groups around the world, and the results were received with frenzied 
interest by both the public and scientific community. A family history of the disease 
is one of the strongest risk factors for breast cancer, implying a genetic component 
to its aetiology. Around 5% of all cases can be attributed to high penetrance genes 
and the two known breast cancer susceptibility genes, BRCA-1 and -2, account for 
90% of this number (Slattery and Kerber, 1993). As might be predicted from 
previous work, germline alterations in these genes are associated with an autosomal 
dominant breast cancer predisposition. BRCA-1 was cloned following classical 
linkage analysis between marker D17S174 on chromosome 17 in women from large 
cancer families involving breast and ovary (Miki et al., 1994). The existence of 
BRCA-2 was implied from studies of families with a history of female and male 
breast cancer where linkage to the D17S174 marker was not seen. Evidence was 
subsequently forthcoming of linkage to 13q and, in 1995, the BRCA-2 gene was 
cloned (Wooster et al., 1995). The two genes have similar lifetime risk for breast 
cancer (60-85%), but the risk of ovarian cancer is higher in BRCA-1 (~40%), 
whereas BRCA-2 alone carries a risk of male breast cancer (Marcus et al., 1996). 
Clearly, identification of these genes allows accurate quantification of risk within 
families with the mutation. The utility of a negative test in women who are at risk of 
carrying a breast cancer susceptibility gene is much less certain. In addition, the 
therapeutic options for proven carriers viz., bilateral prophylactic mastectomies or 
chemoendocrine prevention, are not entirely satisfactory.
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Table 1.2 Cancer predisposition syndromes and their genetic basis
Gene Disease/Syndrome Cancer Type Chromosomal
location
APC FAP and Gardiner syndrome Colon 5q21
AR Male breast X qll-12
ATM Ataxia telangiectasia Multiple Uq21
BLM Bloom’s syndrome Multiple 15q26
BRCA1 Breast and ovary 17q21
BRCA2 Breast 13ql3
CDK4 Melanoma 12ql3
CDKN2A/MTS2 Melanoma 9p21
DPC4 JPS Colon 18q21.1
E-CADHERIN Stomach 16q22
ER Breast 6q23
IGFII Beckwith-Wiedemann 
syndrome
Multiple l lp l5
hMLHl HNPCC Colon 3p21
hMSH2 HNPCC Colon 2pl6
hPMSl HNPCC Colon 2q31
hPMS2 HNPCC Colon 7p22
p57KIP2 Beckwith-Wiedemann 
syndrome
Multiple l lp l5
LKB1 PJS Multiple hamartomata 19pl3
MEN1 MEN type 1 Multiple endocrine l lq l3
MET HPRC Renal 7q31
NF1 Neurofibromatosis typel von 
Recklinghausen’s disease
Neural crest 17qll
NF2 Neurofibromatosis type 2 Schwannoma 22ql2
PTCH Gorlin’s syndrome/ BCNS Skin 9q22
PTEN/MMAC1 BZS, CD, JPS, LDD Multiple hamartomata 10q23
RBI Retinoblastoma 13ql4
RET MEN type 2A and 2B Multiple endocrine lO qll
TSC1 Tuberous sclerosis Multiple 9q34
TSC2 Tuberous sclerosis Multiple 16pl3
TP53 Li-Fraumeni syndrome Multiple 17pl3
VHL von Hippel-Lindau disease Renal 3p25
WRN Werner’s syndrome Multiple 8 p ll. 1-21.1
WT1 Wilms’ tumour/Denys-Drash 
syndrome/WAGR
Renal l lp !3
XPA-G Xeroderma Pigmentosum Skin
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The DNA mismatch repair genes, germline mutations in which are responsible for 
the clinical syndrome of HNPCC, conform to the paradigm of other TSGs, yet 
nevertheless are felt to represent a distinct class or subclass of cancer genes. 
Observation of microsatellite instability in a proportion of bowel cancers (both 
inherited and sporadic) eventually resulted in the discovery of four genes that 
function to repair replication errors in DNA which are missed by the exonuclease 
activity of DNA polymerase (Liu et al., 1995, 1996). Such a replication error (RER) 
positive phenotype is relevant to the treatment of these tumours: they appear 
intrinsically resistant to ds-platinum, and indeed treatment with alkylators may 
promote DNA instability. The concept of a hypermutable phenotype was first 
proposed by Loeb (Loeb, 1991), who felt that such a mechanism was required to 
account for the high mutation rate seen in cancer cells. One can imagine the result as 
being the acceleration of the whole process of tumorigenesis with fast emerging 
novel clones being selected on the basis of a growth advantage. This notion has both 
strengthened and refined the overarching hypothesis of cancer as a genetic disease of 
cells that requires a number of cumulative mutations before true invasion and 
metastasis is seen.
There are four other important genes whose disruption results in the Mutator 
phenotype. These are ATM, XPA, BLM and WRN. Each is associated with and was 
indeed discovered through the study of cancer disposing syndromes. Ataxia 
telangectasia (A-T), so named from two of the several conspicuous clinical signs 
observed in sufferers of the condition, confers a lifetime risk of cancer of around 
40%, commonly leukaemia and lymphoma (Morell et al., 1986). Cells from A-T 
patients examined microscopically are phenotypically abnormal, exhibiting 
macronucleus and demonstrating marked radiosensitivity. Indeed, for several years 
radiotherapists have known that exposing A-T patients to conventional doses of 
radiation has serious sequelae, seen only in normal subjects after very high doses. 
Cytogenetically, lymphocytes from homozygous mutant A-T patients show 
chromosomal abberations such as translocations and inversions (Kojis et al., 1992) 
whose numbers increase as a consequence of irradiation. A provocative observation
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is that these cells have defective DNA damage checkpoints, and lack a rise in p53 
after irradiation, suggesting a role for the ATM protein in DNA damage response 
upstream of p53.
Whereas in some ways radiation sensitivity in A-T subjects is a laboratory artefact, 
since most will not be exposed to ionising radiation, exquisite photosensitivity is an 
integral part of the lives of xeroderma pigmentosum (XP) patients. XP is the 
prototype DNA repair defect syndrome. It results from defects in the nucleotide 
excision repair (NER) pathway which is only now becoming unravelled and 
understood. XP in fact comprises a group of genetic disorders (de Weerd-Kastelein 
et al., 1972), and all seven genes have now been cloned (termed XPA-G). Two of 
these, XP B and D, encode DNA helicases. The genes BLM and WRN, defects in 
which cause the clinical syndromes of Bloom and Werner respectively, likewise 
encode helicases, although their physiological role is presently unclear. Certainly, 
these syndromes have cells which characteristically show genetic instability.
The discovery of genes which, though involved in cancer, do not themselves result 
directly in the transformed phenotype, has led to the proposal of the ‘caretaker vs 
gatekeeper’ hypothesis (Kinzler and Vogelstein, 1997). As elaborated by Kinzler 
this posits a caretaker class of TSGs whose role it is to maintain the integrity and 
stability of the genome and whose disruption leads to the mutator phenotype. 
Clearly, ATM, and the genes described above would belong to this group. On the 
other hand, gatekeepers are those genes which directly act to inhibit growth or 
promote cell death, and whose identity varies from tissue to tissue e.g. VHL in 
kidney cancer and APC in colon cancer. In some instances (such as the BRCA genes) 
assignment to one or other group is, on the basis of current evidence, not clearcut. 
Nevertheless, the description serves as a useful conceptual framework to facilitate 
understanding.
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1.2 Animal Models in the Study of Cancer
The use of model organisms in the study of human disease is well established. Many 
disease phenotypes (both spontaneous and artificially produced) have been described 
in a wide variety of species, including fruitflies, zebrafish, pigs, rabbits, rodents and 
primates. Although studies in fruit flies and nematodes have yielded valuable and 
widely relevant information on developmental biology, the general utility of such 
evolutionary distant organisms to understanding human disease entities is limited. 
Mammalian models are clearly preferable by virtue of a more closely related 
physiology, and primates might be expected to fit the bill best of all. However, for 
reasons of expense, fecundity and significant ethical concerns over primate 
experimentation, the animal model par excellence has been and remains the humble 
housemouse, Mus musculus.
The mus genus has much to commend it as a model organism: ease of breeding, 
short lifespan and large numbers of offspring all facilitate laboratory handling and 
experimentation. Thanks to experience stretching back over several decades, mouse 
genetics are extremely well understood and, crucial to the mapping of novel genes, 
there exists a dense map of the mouse genome (Dietrich et al., 1996). Of particular 
importance, large stretches of chromosomes show conserved gene and marker 
linkage (synteny) with human and other mammalian genomes. This is relevant since 
detailed mapping of mouse should aid investigation of homologous genes in 
humans. A high degree of conservation is often also evident at coding regions 
between mouse and man. Theoretically then, DNA probes and primers developed in 
one species would be expected to be useful and applicable to the other, and this is 
indeed true in practice.
Mice are beloved by geneticists because of the ease with which complex breeding 
protocols can be set up (table 1.3 and figure 1.4). This has been crucial to the placing 
of mutant phenotypes and clones on the mouse genetic map. Classically, mouse
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mapping had been done one locus at a time with the introduction of a mutation into a 
strain with another phenotypic marker, followed by breeding experiments to 
determine linkage. More recently, mapping panels have been employed. These are 
sets of DNA from mice with randomly recombined chromosomes produced by 
specific breeding protocols. Classic examples of such protocols are the interspecific 
backcross and recombinant inbred strains (Figure 1.4).
Table 1.3 Categories of Genetic Cross
Types of Mating Offspring Genotype Uses
Outcross A/A x a/a A/a Production of FI hybrids
ala2 x a3a4 ala3, ala4, a2a3, a2a4
Backcross A/a x a/a A/a, A/A Linkage analysis
A/a x A/A A/a, a/a
Incross A /A x A/A A/A Maintenance of inbred strain
a/a x a/a A/a
Intercross A/a x A/a A/a, A/A, a/a Linkage analysis
The discovery of the microsatellite marker was hailed by geneticists as the advent of 
the magic bullet. These simple repeat sequences, consisting of di-, tri- or tetra- 
repeats, were discovered to be present at high density throughout mammalian 
genomes and, crucially, had unusually high polymorphic content. They therefore had 
distinct advantages over the basepair substitution type of polymorphism, as 
exemplified by restriction fragment length polymorphisms (RFLP) and, combined 
with the ease with which they could be assayed using PCR, quickly became the 
genetic tool of choice for mapping. Figure 1.5 illustrates the length polymorphism of 
microsatellites.
Interspecific crosses (crossbreeding between M. musculus and wild mouse strains) 
have led to major advances in mouse genetics (Bonhomme et al., 1979; Copeland 
and Jenkins, 1991). Whereas use of intraspecies crosses between different musculus 
strains is hindered by relatively little genetic difference, interspecific FI mice are 
‘superheterozygous’ at virtually every marker. Aside from its implications for 
genetic mapping, this permits allelotyping to be performed and identification of loss 
of heterozygosity (Figure 1.5). Using simple microsatellite length polymorphisms
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ALLELES
B
 CACACACACACACACACACACACACACACACACACA—
"CACACACACACACACACACACACACACACACACACACAC7T
■CACACACACACACACACACACACACACACACACACACACACAC7T
LOH: 
Loss of C
B C A/B A/C B/C mB/C cross
Figure 1.5. Depiction of microsatellite repeats of the (CA)n variety used as polymorphic 
markers in LOH studies. The polymorphism (e.g. between M. musculus strains or A, B and 
C in figure) resides in the number of CA repeats and therefore their length as assayed by 
PCR. Arrows represent PCR primers used in the amplification. Provided a mouse is 
heterozygous at a particular locus (M. musculus x  M. spretus crosses virtually always are), 
LOH will be seen as an absence of a band on gel resolution (far right example).
21
assayed by PCR, parental alleles can be separately identified and followed. This is 
particularly applicable to allelotyping of chemically induced tumours in interspecific 
FI mice, and is described below.
Most of the phenotypic variation between individuals is not of the ‘all or none’ 
variety that characterises Mendelian traits, but rather exists over a continuum. It is 
these traits which are of most interest to geneticists, and examples would include 
height, hair colour, longevity and, apropos cancer, tumour susceptibility. Although 
cancer families exhibit germline mutations in tumour suppressor genes which are 
transmitted in a classic Mendelian fashion, this is rare and accounts only for a small 
minority of human cancers. The likelihood is that cancer susceptibility is a polygenic 
phenomenon resulting from the combined effect of multiple low penetrance genes. 
The role of such genes in the development of cancer is arguably best studied in the 
mouse where a number of inbred strains show markedly differing susceptibility to 
cancer development, both spontaneous and induced. The use of mouse selective 
breeding protocols in combination with modern statistical techniques that allow 
modeling of quantitative trait loci has already resulted in the identification and 
mapping of a number of mouse tumour modifier loci, influencing tumour size, 
growth rate and other characteristics (Nagase et al., 1995).
The mouse as model system has found renewed favour with the advent of germline 
manipulation technology. Pioneered in the 1980s, the technique of zygote 
pronuclear injection permitted the stable introduction of any gene into the germline 
of mice. ES cell technology has refined the technique further, permitting specific 
mutations to be engineered (Capecci, 1989; Melton, 1994). These experiments were 
crucial to exploring the role of oncogenes in carcinogenesis and in examining 
consequences of tissue specific oncogene expression. They also provided 
compelling evidence for cooperation between oncogenes in tumorigenesis by 
observing the offspring of crosses between two transgenic mice. For example, a 
synergistic action was observes between H-ras and myc when transgenes under the 
control of the MMTV promotor were expressed in breast epithelia (Sinn et al.,
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1987). Application of the technique is clearly not confined to cancer research and 
has found particular use
commercially in generation of ‘bioreactors’ (Moffat, 1991) which produce large 
quantities of valuable proteins such as factor VIII.
Table 1.4 Knockout mice and their associated phenotype
Gene Function____________________________Tumour phenotype
Rb Cell cycle regulator Pituitary adenocarcinomas, 
MTC, phaeochromocytoma
p53 Transcription factor, 'guardian of the 
genome'
Lymphoma, sarcoma
Wt-1 Transcription factor None
APc Binds fl-catenin Intestinal polyps
Nf-1 ras-GAP activity Phaeochromocytoma, myeloid leukaemia
Nf-2 ERM cytoskeletal regulator Sarcoma
Ink4a Encodes p l6 and p i9 ^ Lymphoma, sarcoma
p i  9 Binds mdm2, induces p53 Lymphoma, sarcoma
Brcal Binds Brca-2 and RadSI; DNA repair? None
Brca2 Binds Brca-1 and RadSI; DNA repair? None
Smad4 TGF-|3 signal transducer None
Dec Netrin-1 signal transducer None
Msh2 Mismatch repair Lymphoma, colon and skin carcinomas
Msh6 Mismatch repair Lymphoma, intestinal adenocarcinoma
Pten Lipid phosphatase Thyroid and prostate hyperplasia, lymphoma
Investigation into the function and actions of tumour suppressor genes requires the 
ability to disrupt (knock out) both functioning copies of a gene. Such gene targeting 
is now routinely performed and the resultant knock-out mice are invaluable tools in 
the study of TSGs. Indeed these mice may serve as models for human cancer 
predisposition syndromes (table 1.4). One of the first was the Rb knockout mouse 
(Jacks et al., 1992; Clark et al., 1992). Interestingly, loss of Rb does not in the 
mouse result in retinoblastoma; these mice die of pituitary adenocarcinomas, 
medullary thyroid carcinaoma and phaeochromocytomas without any evidence of 
retinal pathology (Harlow, 1992). One suggestion, supported by the observation that 
transgenic expression of SV40 T antigen induces retinoblastomas, is that Rb related 
proteins, pl07 and pl30, require to be inactivated. Rb -/+; pl07 -/- chimaeric mice
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do indeed develop retinoblastoma (Robanus-Maandag, 1998), but tumours seem to 
arise from a different cell layer to those related to T antigen overexpression. As can 
be seen from the Brca-1 and -2  knockouts, this technology does have its limitations: 
no detectable tumour phenotype can be correlated with knockouts in these genes.
1.2.1 The Mouse Carcinogenesis Model
The observation over fifty years ago that skin cancers in mice can be induced 
consistently and reproducibly by topical application of a number of organic 
chemicals paved the way for the development of a valuable and powerful tool in the 
field of cancer research. Although not the only animal chemical carcinogenesis 
system available (table 1.5), for reasons of ease of application and observation, the 
mouse skin two stage carcinogenesis model has become one of the most widely used 
and best understood. Indeed, much of the early evidence in support of the multistage 
development of cancer came from observations in this system (Peraino et al., 1975; 
Becker, 1975; Burns et al., 1983).
Table 1.5 Animal chemical carcinogenesis models of human cancer
?ecies_________________ Agents
Mouse, rat Nitrosamines, alkylating
agents, aromatic amines, PAH 
Liver Hamster, guinea pig DMBA
Lung Mouse, rat, hamster, dog Nitrosamines, asbestos, PAH
Breast Mouse, cat, dog
Colon Mouse, rat
Pancreas Rat, hamster
Bladder Mouse, rat, hamster
DMBA, aromatic amines, 
NMU
Nitrosamines
Nitrosamines
Nitrosamines, aromatic amines
rumour t ype 
Squamous cell cancer, basal 
cell cancer 
Melanoma
Adeno- and squamous cell 
carcinoma, mesothelioma 
Adenocarcinoma
Adenocarcinoma 
Adenocarcinoma 
Urothelial cancer
Observations made using mouse and other systems allow the carcinogenesis process 
to be divided into three operational steps: initiation, promotion and progression 
(Yuspa and Dludosz, 1991). A single application of an initiator results in an 
irreversible, heritable change in the cells which is not phenotypically evident.
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Multiple applications of a promoter will produce numerous benign (but 
preneoplastic) papillomas, 5-10% of which will spontaneous progress to carcinomas. 
Both squamous carcinomas and the more aggressive and less well differentiated 
spindle cell carcinomas are formed. The genetic events underlying each of these 
steps have begun to be unraveled.
1.2.1.1 The initiation process
That most potent initiators are mutagens, that the process is to some degree dose- 
dependent and that the initiated state persists for some time (and is often 
irreversible), all points to a genetic basis for initiation. The classic approach to 
experimental induction of skin tumours was painting with coal tar but this has now 
been superceded by application of the pure chemical carcinogen. Presently, 
commonly used compounds in the process of initiation are 7,12- 
dimethylbenzanthracene (DMBA) and N-methyl-N’-nitro-N-nitrosoguanidine 
(MNNG). Although their use results in no immediately obvious phenotypic change 
in the context of intact skin, initiated keratinocytes in vitro display an altered 
response to signals for terminal differentiation (Yuspa and Morgan, 1981). This fact 
has allowed isolation and detailed molecular analysis of initiated cells in culture, and 
has led to some remarkable observations. It became apparent that over 90% of 
DMBA initiated cells from papillomas carried an identical A-T transversion in 
codon 61 of H-ras and that the same mutation was present in pretumorous but 
initiated cells (Quintanilla et al., 1986). It is of particular note that many 
spontaneous human skin tumours, both benign and malignant, exhibit the same 
mutation. Proof that this mutation was causal came from crucial observations made 
by Balmain and colleagues, who found that introduction of mutant ras could 
substitute for chemical initiation (Balmain and Pragnell, 1983).
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1.2.1.2 Promotion
In contrast to initiation, the process of promotion is reversible and requires repeated 
application to be effective. In addition, most tumour promoters are not detectably 
genotoxic. This would suggest that the process is an epigenetic phenomenon. 
Tumour promotors can be identified by their ability to reduce the latency period to 
the development of preneoplastic and neoplastic lesions after application of 
initiators. They do not require metabolic activation and are to some degree tissue 
specific (table 1.6). In general terms most promoters act to induce cellular 
proliferation (Burns et al, 1983); indeed ‘wounding’ has been known for some time 
to take the place of a promoting agent. The explanation advanced to account for their 
general mode of action, now widely accepted, is that they cause selective clonal 
expansion of an initiated cell population which in turn provides an increased number 
of cells that are targets for further changes in the neoplastic process. The phorbol 
ester TPA is one of the most potent promoters known, and is thought to exert its 
effects on cell proliferation partly by interacting with Protein kinase C (PKC) 
(Castagna et al., 1982). In normal cells, exposure to TPA results in accelerated 
differentiation whereas initiated cells are resistant to PKC mediated differentiation. 
It seems likely that by allowing continued proliferation, further genetic events are 
permitted to take place.
Table 1.6 Site specificity of promoting agent
Initiation______________ Promotion Tissue Site
BHBN Phenobarbital
Saccharin
NMU Phenobarbital
Saccharin
4-Acetylaminostilbene
Phenobarbital 
DDT
 _______  DES_______ _
Other molecular events are clearly involved at this stage. Tumour promoters are 
recognised as causing aneuploidy. Trisomies of chromosomes 6 and 7 are a 
common observation in papillomas and carcinomas (Aldaz et al., 1989), implying
Liver 
Bladder 
Liver, thyroid 
Bladder
Sebaceous glands
Liver
Liver
Liver, breast
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that they harbour genes important to the neoplastic process. Trisomy of chromosome 
7 is thought to duplicate the mutant ras allele, conferring selective advantage to an 
initiated cell. Loss of all or part of chromosome 6 has also been seen. The gene(s) 
involved here have however yet to be isolated.
1.2.1.3 Malignant Progression and the Squamous-Spindle Transition
Papillomas that appear following initiation and promotion may be divided into high 
risk and low risk groups on the basis of the likelihood of progression to malignant 
tumours. Papillomas of the high risk class tend to erupt early, grow to a large size 
and fail to regress following withdrawal of promoter (Hennings et al., 1990a). 
Phenotypic markers can also help distinguish them: they express cytokeratin K1 
rather than the K13 antigen commoner on low risk tumours (Nischt et al., 1988), and 
they lack TGF[31 and 2 (Glick et al., 1993). The TGFp group of growth factors 
interacts with the cognate receptor thereby inhibiting growth in normal keratinocytes 
and other epithelial systems, including colon. Although the genetic basis for these 
different characteristics is not known, that this stage of progression is genetically 
controlled is suggested by the ability to produce a higher rate of malignant 
progression with the application of carcinogens. In the future these genetic 
differences may be identified by novel molecular techniques, such as genomic array 
comparative genome hybridisation (CGH) (Kashiwagi and Uchida, 2000) or SNP 
(single nucleotide polymorphism) analysis (Lai, 2001).
Spindle cell carcinomas, so-called from their fibroblast like morphology, are poorly 
differentiated tumours thought to arise from squamous cells. They invariably lack a 
range of cell surface differentiated markers, such as integrins and cell adhesion 
molecules. The genetic basis for the transition again remains to be elucidated, but a 
high proportion of spindle cell lines have undergone homozygous deletion at the 
pl6/CDKN2A locus. It has been suggested that metastasis may occur via a spindle 
cell intermediate, though firm evidence for this is lacking.
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1.3 Multistep Carcinogenesis
The question arises as to whether inferences can be made about human epithelial 
cancer from data derived from the mouse skin chemical carcinogenesis system. 
Thankfully all the indications are that they can: the range of genes altered in the 
mouse skin system is the same as is found in spontaneously occurring human 
cancers; treatment with carcinogens, rather than forcing cells to transform, merely 
accelerates changes that take place spontaneously, albeit at a much slower rate; and, 
similar sequential genetic changes are observed in cancers of other epithelia, 
particularly the urogenital, digestive and aerorespiratory tracts.
The three commonest genes altered in the mouse skin system are H-ras, p53 and 
p l6 . As discussed above, mutation of H-ras is seen as an early, initiating event in 
skin tumorigenesis. p53, residing on mouse chromosome 11, appears to be altered at 
a later stage of tumour development, often in high grade squamous cancers. 
Interestingly, p53 mutation may be more common in the smaller percentage of 
squamous carcinomas that retain TGF(3 expression, perhaps conferring resistance to 
this growth inhibitor. In any case, p53 alterations appear to occur as a late event. 
Likewise, p l6 , which appears homozygously deleted in a high proportion of spindle 
cell carcinomas, is altered as a late event.
Useful parallels can be drawn between the mouse skin model and the human 
multistep process, as paradigmed in the genetic model of colon cancer. The 
acquisition of sequential mutations in the dysplasia-benign papilloma-invasive 
carcinoma procession, first described and elaborated by Kinzler and Vogelstein 
(1996), is the best known and most detailed carcinogenesis model in man. The 
theory serves to unify much of what is known about oncogenes, tumour supressor 
genes and mutator genes. The initiating event is a mutation in the APC gene which 
is seen as a gatekeeper to subsequent events. The obvious parallel in the mouse 
system would be H-ras. The ras family of oncogenes seems also to be involved in 
human colon cancer, but at a later stage, with 50% of large adenomas possessing
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mutations in N- or K-ras. Interestingly, these changes are also seen occasionally in 
hyperplastic polyps and collections of normal cells. This serves to reinforce the 
notion that the critical event is an alteration in APC and that cooperation between 
genes is crucial: in the presence of an APC mutation, ras contributes to 
transformation, which can be reversed by reintroduction of normal ras gene. p53 is 
involved in human colon cancer as a late event, in common with the changes in 
mouse skin. A schematic of these changes, highlighting similarities, is shown in 
figure 1.6.
1.4 Gene Cloning
The possession of biochemical data, or even purified protein from which sequence 
information can be inferred, is not usually a luxury enjoyed when attempting to 
identify a cancer-associated gene. The typical starting point is an indication of the 
chromosomal or perhaps subchromosomal location of the gene. This can be derived 
from the discovery of cytogenetically visible chromosome abnormalities in 
individuals with the disease, or by formal (and laborious) linkage analysis. Linkage 
is a function of genetic recombination at meiosis, and simply implies that two DNA 
sequences are inherited together because of physical proximity. Linkage data as 
generated by computers are expressed as LOD scores (logarithm of the odds of 
linkage, Z). These methods of generating positional data apply to any disease-related 
gene. The technique of LOH, and the related homozygous deletion, is specific to 
TSGs and is particularly relevant to the study of sporadic cancers. Invoking once 
again the ‘two hit’ model, the first hit is commonly a mutation or other relatively 
subtle change. The hit on the second allele, however, is often much less discreet and 
may involve loss of a whole chromosome, or a large deletion (as might be detected 
cytogenetically). Cavanee and colleagues (1986) gave a comprehensive description 
of the means whereby this inactivating event might occur (figure 1.7). Closely 
linked genetic markers would also be expected to be lost in this deletion and, if the 
patient is heterozygous for a marker at a particular locus, the event can be observed
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as LOH. Following markers for which a patient is homozygous is of course 
noninformative. Employing highly polymorphic markers such as microsatellites 
greatly facilitates the search for LOH since most patients will be heterozygous for 
any given marker chosen. As already described, interspecific crosses between mice 
results in a ‘ superheterozygous’ state in the offspring, making LOH analysis simple 
to perform in FI progeny.
The use of positional data to identify a gene is known as positional cloning. Often, 
and particularly in the context of the human genome project, genes are known to 
exist in the area of interest, and these candidates can then be investigated for 
evidence of disease association. It is expected that on completion of the human 
genome project, the positional candidate gene approach to identifying human cancer 
(and other) genes will be the most efficient and therefore the preferred method.
Generation of high resolution mapping data for the gene of interest is commonly the 
rate limiting step in the process. A sine qua non of positional cloning is possession 
of a large number of polymorphic markers which can be used to generate such a 
map. Clones are required which span the region of interest, from which physical 
maps can be derived. If contigs (contiguous clones) have not already been generated, 
they require to be constructed - a formidable and time-consuming task. Again, due 
mainly to human genome project, much of this work has now been performed: large 
insert clones such as YACs or PACs exist for much of the human genome which can 
be subcloned into smaller, more manageable fragments e.g. cosmids for further 
analysis. Sequence data in public databases may also point to the presence of genes 
within the cloned region, facilitating the positional candidate gene approach.
Once achieved, however, the candidate genes so identified must be rigorously 
examined for evidence of involvement in the disease. Good circumstantial evidence 
of involvement might be expression of the gene in the tissue of interest. For 
example, failure to find corresponding mRNA in breast in a candidate breast cancer 
gene would not bode well. A more specific means is to screen for mutational
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alteration of the gene in the cancer of interest from a number of affected cases. This 
can be done rapidly and with acceptable sensitivity by the technique of single strand 
conformational polymorphism (SSCP) which aims to identify any difference from 
the normal sequence (see 4.2 for a fuller description of this). Functional assays 
provide a compelling argument that the gene of interest has been found. 
Reintroduction of a TSG into a cell with subsequent suppression of the malignant 
phenotype would provide this supporting evidence, and subsequent reversion upon 
loss of the gene would be stronger evidence still. Animal models might provide 
further positive data. Creation of a transgenic mouse with a phenotype resembling 
the disease would obviously be supportive of the case.
The technique of subtraction cloning, and its modern corollary RDA (Lisitsyn et al., 
1993; Lisitsyn and Wigler, 1995), provides a method of scanning an entire genome 
for differences from normal DNA. Although technically difficult to perform, it has 
had a number of notable successes: dystrophin and PTEN (Li et al., 1997) were both 
identified in this way. It is expected that this technique, combined with microarray 
technology, will accelerate our understanding of the genetics of cancer.
1.5 Aims
A large body of evidence points to the existence of a TSG on the long arm of human 
chromosome 7. Frequent loss of heterozygosity has been reported in a variety of 
human cancers, including breast, ovarian, gastric, pancreatic and haematological 
malignancies, and these data have been supported by cytogenetic studies (reviewed 
in Zenklussen and Conti, 1996). In common with other TSGs, the putative gene 
seems to be conserved in other species such as mouse, since a high frequency of 
allele loss has been seen in mouse squamous tumours in the region of mouse 
chromosome 6 syntenic with human 7q31 (Zenklussen et al., 1994). Furthermore, 
inhibition of tumorigenesis has been demonstrated by chromosome transfer of 
human chromosome 7 into murine squamous carcinoma cell lines (Zenklussen et al.,
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1994), indicating that the encoded protein is highly conserved between these two 
species.
The aim of this work was to identify and clone the putative multi-tissue TSG on 
mouse chromosome 6. Firstly, I chose to confirm and extend the published LOH 
data from the mouse skin system and define a region of interest. This was achieved 
by saturating the area of interest with all published microsatellite markers. Next, 
utilising data from concurrent research on human chromosome 7 within our 
laboratory, I aimed to identify and examine mouse homologues of human candidate 
tumour suppressor genes. Finally, having cloned a number of such genes, I 
examined their potential as candidate tumour suppressor genes.
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CHAPTER2 
MATERIALS AND METHODS
35
2. Materials and Methods
2.1 Materials
2.1.1 Chemicals
All chemicals not listed below were obtained (AnalaR grade) from BDH 
Chemicals Ltd., Poole, Dorset, UK. Solutions and buffers were prepared using 
de-ionized water (dFLO) obtained from a Millipore MilliRO 15 system.
Chemical Source
Redivue [a-32P] dCTP~3000Ci/mmol Amersham International pic., 
Amersham, Buckinghamshire, UK
CsCl Boehringer Mannheim UK,
Hepes Lewes, East Sussex, UK
Mops
Butan-l-ol Fisher Scientific UK. Ltd.,
Chloroform Loughborough, Leicestershire, UK
38% (w/v) Formaldehyde
Propan-l-ol
Dimethyl formamide Fluka Chemika-Biochemika AG, 
Buchs, Switzerland
Ethanol James Burrough Ltd., 
Witham, Essex, UK
Tris Life Technologies Ltd.,
Trizol Paisley, UK
Deoxyribonucleotides Promega, 
Southampton, UK
Water-saturated phenol Rathburn Chemicals Ltd., 
Walkerburn, UK
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Chemical Source
Bovine serum albumin (BSA) Sigma Chemical Co.
Bromophenol blue Ltd.,
C uS04 Poole, Dorset, UK
DEPC
Dithiothreitol
Ethidium bromide
MES
NP40
TEMED
Tween 20
2.1.2 Enzymes
All DNA modifying enzymes and their buffers, except those listed below, were 
obtained from Life Technologies Ltd., Paisley, UK.
Enzyme Source
Klenow polymerase Boehringer Mannheim UK,
Proteinase K Lewes, East Sussex, UK
NovoZyme Novo BioLabs, 
Bagsvaerd, Denmark.
Dnase-free RNase A Sigma Chemical Co. Ltd., 
Poole, Dorset, UK
Taq polymerase Bioline, 
London, UK
T4 DNA ligase Northumbria Biologicals Ltd., Cramlington, 
Northumberland, UK
2.1.3 Kits
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Kit Source
HighPrime random-priming labelling Boehringer Mannheim UK,
mixture Lewes, East Sussex, UK
TA-cloning kit Invitrogen,
NV Leek, Netherlands.
First strand cDNA synthesis kit Life Technologies, 
Paisley, UK
Geneclean II BIO 101 Inc., 
Vista, CA, USA
ABIPRISM DNA sequencing kit PE Applied Biosystems, 
Warrington, UK
2.1.4 General plasticware
Source
Filter pipette tips Greiner Labortechnik Ltd., 
Gloucestershire, UK
Falcon tubes Becton-Dickinson Labware, 
Plymouth, UK
5 ml bijous Bibby-Sterilin Ltd.,
20 ml universals Staffordshire, UK
microcentrifuge tubes Elkay,
pipette tips Galway, Eire
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2.1.5 Miscellany
Source
MicroSpin S-200 and S-400 HR 
columns
Pharmacia Biotech. Inc., Herts., UK
Sonicated, denatured genomic DNA 
from human placenta 
Torula yeast RNA type VI
Sigma Chemical Co. Ltd., 
Poole, Dorset, UK
FITC labelled STAR FISH whole 
mouse chromosome paints
Cambio Ltd., Cambridge, UK
2.1.6 Electrophoresis gels
Source
Agarose, ultrapure, electrophoresis 
grade
Life Technologies, 
Paisley, UK
Polyacrylamide Severn Biotech Ltd., 
Kidderminter, UK
Sequagel BS+S
Edinburgh, UK
2.1.7 Molecular weight markers
Marker Source
(j)X174 DNA/ Hae III fragments Life Technologies Ltd.,
X DNA/ Hind III fragments Paisley, UK
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2.1.8 Paper, membranes, and X-ray film.
Source
Hybond nylon membranes Amersham International pic., 
Amersham, Buckinghamshire, UK
3MM filter paper Whatman International Ltd., 
Maidstone, Kent, UK
X-ray film (X-OMAT-AR) Eastman Kodak Co., 
Rochester, New York, USA
2.1.9 Microbial host, media, and supplies.
Sterile glassware and Luria (L)-broth (Maniatis et a l,  1989) were prepared by 
Beatson Institute for Cancer Research (BICR) central services.
Source
Petri dishes Bibby-Sterilin Ltd.,
Staffordshire, UK
Bacto-agar Difco,
Bacto-peptone Detroit, MI, USA
Bacto-yeast extract
Tryptone
Yeast nitrogen base without amino
acids
DH5a competent E. Coli Life Technologies,
NZY broth Paisley, UK
Ampicillin Sigma Chemical Co. Ltd.,
Kanamycin Poole, Dorset, UK
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2.1.10 Plasmid vectors
Vector Source
pBluescript SK (+/-) Stratagene Ltd.,
Cambridge, UK.
2.1.11 Libraries
Library Source
Mouse fetal brain cDNA library Stratagene Ltd.,
Mouse B6 genomic library Cambridge, UK
2.1.12 Cell culture media and supplies
Sterile glassware, PE, PBS and water were prepared by the Beatson Institute for 
Cancer Research central services.
Source
Freezing vials A/S Nunc, 
Roskilde, Denmark
Cell culture plastic dishes Becton-Dickinson Labware, 
Plymouth, UK
FCS Bioclear UK Ltd. 
Devizes, Wilts, UK
DMSO Fisher Scientific UK. Ltd., 
Loughborough, Leicestershire, UK
L-glutamine Life Technologies, Paisley, UK
Trypsin
DMEM Sigma Chemical Co. Ltd.,
Penicillin Poole, Dorset, UK
Sodium bicarbonate
Sodium pyruvate
Streptomycin
2.1.13 Cell lines
The cell lines listed below were kindly provided by Professor A. Balmain, CRC 
Beatson laboratories, Medical Oncology, Glasgow, UK.
Cell Line Description Origin
C5N non-tumorigenic, immortalized cell isolated by single cell cloning of
C50 line MCA3D cells derived from a Balb/c 
mouse
MSCP1 derived from papillomas M. spretus / Mus musculus FI hybrid
B9 squamous explant from the MSC11 
carcinoma
Mus spretus / Mus musculus FI 
hybrid mouse (single cell clone)
A5, D3 spindle explants from the MSC11 
carcinoma
Mus spretus / Mus musculus FI 
hybrid mouse (single cell clones)
CarB, carC highly aggressive spindle cell lines 
isolated from carcinomas
NIH mouse
SN161 squamous / spindle mixed 
morphology derived from a lymph 
node metastasis
129/N IH  mouse
E4 squamous cell line single cell cloning of SN161
Hll spindle cell line single cell cloning of SN161
PDV squamous cell line keratinocyte isolated from C57BL 
mouse and transformed in vitro by 
DMBA
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2.1.14 Mouse skin tumour samples
Mouse skin tumours were gifted to me by Professor A. Balmain, CRC Beatson 
laboratories, Medical Oncology, Glasgow, UK. Tumours were induced and 
harvested as follows: all mice were bred in-house and given food and water ad 
libitum. The dorsal area of 7 to 10 week old mice was shaved and tumours 
induced by twice-weekly application of DMBA, or alternatively a single 
application of DMBA followed by twice-weekly applications of TPA. 
Occasionally, animals treated with DMBA and TPA were also treated with 
MNNG. Carcinomas were removed as they appeared and frozen, and any 
papillomas present were also removed. DNA was isolated from the tumours as 
described in 2 .2 .2 .1 .
2.1.15 Websites
Genome Data Base:
http://gdbwww.gdb.org
Jackson Laboratory:
http://www.informatics.jax.org/
National Center for Biotechnology Information (NCBI): 
http://www.ncbi.nlm.nih.gov
Whitehead Institute/MIT Center for Genome Research: 
http://www-genome.wi.mit.edu/
43
2.2 Methods
2.2.1 Cell culture
Cell lines derived from mouse skin or from epithelial tumours were routinely 
maintained at 37°C in sealed plastic flasks containing Special Liquid Medium 
(SLM) supplemented with 10% foetal calf serum (FCS) and 2mM glutamine in 
an incubator adjusted to 5% CO2. Cells were routinely passaged when 
subconfluent by aspirating the medium, washing once with PBS then adding a 
small volume of trypsin (10% v/v trypsin, 0.01% EDTA) in PBS. They were 
incubated at 37°C until the cells detached. The cells were then resuspended in 
fresh serum-containing medium to inactivate the trypsin, and reseeded at the 
appropriate dilution.
Cell cultures were routinely monitored for Mycoplasma infection by DAPI 
staining, and were found to be negative.
2.2.2 Nucleic acid preparation and quantitation
2.2.2.1 Extraction and purification of mouse genomic DNA
Genomic DNA was prepared from mammalian cell lines according to Laird et al. 
(1991). Cells were first harvested by trypsinisation and then pelleted by brief 
centrifugation in a microcentrifuge tube. Cells were resuspended and 
simultaneously lysed by trituration in 1 ml of lysis buffer (100 mM Tris.HCl pH
8.5, 5 mM EDTA, 0.2% (w/v) SDS, 200 mM NaCl, 100 jig Proteinase K/ml), 
followed by incubation for several hours at 37 °C with constant agitation. DNA 
was precipitated by addition of an equivalent volume of propan-2 -ol with gentle 
mixing until viscosity was gone. The aggregated precipitate was then removed by 
lifting from the solution with a sterile plastic inoculation loop. Excess liquid was 
dabbed off and DNA was rinsed in 70% (v/v) ethanol. After being allowed 
briefly to air-dry, DNA was dispersed into 0.5 ml TE (10 mM Tris.HCl, 1 mM 
EDTA pH 8.0).
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222.2 Bacterial clone DNA preparation
Cosmid clones were supplied as agar stab cultures. These were first streaked out 
on an L-broth plate (1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 
170 mM NaCl, 1.5% (w/v) agar) supplemented with kanamycin (50 ug/ml). A 
single colony was then used to inoculate a flask containing L-broth and 
kanamycin. For the preservation of bacterial stocks, a 0.5 ml aliquot of over­
night culture in liquid medium was mixed with an equivalent volume of 50% 
(w/v) glycerol, chilled on ice and then stored at -70 °C in plastic cryotubes. 
Cultures were subsequently re-established by inoculation of 5ml of L-broth 
medium, containing the appropriate antibiotic, with 2 0  pi of the glycerol stock.
Plasmid and cosmid DNA were isolated from over-night cultures of transformed 
bacteria by alkaline lysis. Cultures were first refrigerated for 20 minutes before 
being pelleted by centrifugation, and resuspended in the appropriate volume of 
solution I (100 mM Tris.HCl pH 8.0, 100 mM EDTA) (table below). Bacteria 
were then lysed by addition of solution II (0.2 M NaOH, 1% (w/v) SDS) and 
gentle mixing by inversion. After a 5 minutes incubation on wet ice, detergent 
and protein were precipitated by addition of ice-cold solution III (3M KOAc pH 
4.8) and momentary vigorous shaking. After incubating on ice for a further 15 
minutes, the flocculate was removed by centrifugation at 10,000 g. Supernatant 
containing plasmid or cosmid DNA was decanted into a fresh polypropylene 
tube. (For small to medium scale preparations of bacterial clone DNA, RNase 
was added at this stage at a final concentration of 1 0  pg/ml and the lysate 
incubated for 15 minutes at 37°C.) 1/10 volume of chloroform was then added to 
the lysate to remove residual protein, the two phases mixed by shaking, and 
separated by centrifugation. The upper aqueous phase was decanted and DNA 
was precipitated by addition of 0 .6  volumes of propan-2 -ol, followed by washing 
in 70% (v/v) ethanol. DNA was resuspended in TE (pH 8.0).
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Table 2.1 Solution volumes in bacterial clone DNA preparation
Culture volume
1 ml 50 ml 500 ml
Solution I 1 0 0  pi 1 ml 2 0  ml
Solution II 2 0 0  pi 2  ml 40 ml
Solution III 150 pi 1.5 ml 30 ml
2.2.23  Total RNA extraction from mouse cell lines
Extraction of total RNA from cell lines was carried out following the 
manufacturer’s protocol for Trizol. Sub-confluent cells grown in 10 cm dishes 
were washed twice in ice-cold PBS which was completely removed by 
aspiration. Cells were subsequently lysed directly in the dish by the addition of 1 
ml Trizol. A  disposable cell scraper was employed to homogenise the cells, and 
the RNA was solubilised by passing the lysate a few times through a pipette tip 
before being transferred to a fresh microcentrifuge tube. Chloroform was added 
(0.2 ml per 1 ml lysate) and the microcentrifuge tube vortexed for 15 s, then 
incubated on ice for 5 minutes. The samples were centrifuged at 12,000 g at 4°C 
for 15 minutes after which the upper colourless aqueous phase was transferred to 
a fresh microcentrifuge tube and an equivalent volume of propan-2-ol added. The 
samples were stored overnight at -20°C. The RNA precipitate was pelleted by 
centrifugation at 12,000g at 4 °C for 25 minutes. The RNA pellet was washed 
once with 1.5 m l ice-cold 75% (v/v) ethanol by vortexing and centrifugation at 
7,500 g at 4°C for 8  minutes. The RNA was air-dried and re-dissolved in 50 pi 
(DEPC-treated) RNase-free water.
2.2.2.4 First strand cDNA synthesis
First strand cDNA, prepared for RT-PCR, was synthesised using a kit, according 
to the manufacturer’s instructions. Approximately 1 pg of total RNA in DEPC- 
treated H2O was combined with 1 x first strand buffer (50 mM Tris.HCl pH 8.3,
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75 mM KC1, 3 mM MgCl2), 10 mM DTT, and 0.5 mM of each of the four dNTPs 
(dATP, dCTP, dGTP, dTTP), and incubated for 5 minutes at 65°C. The reaction 
mixture was chilled on ice and 1 pi (200 units) of M-MLV reverse transcriptase 
added, followed by incubation at 37°C for 1 hr.
2.2.2.5 Synthesis and Purification of oligonucleotides
Oligonucleotides were synthesised at the BICR as a core service on an Applied 
Biosystems model 392 or 394 RNA/DNA synthesiser using phosphoramidite 
chemistry according to the manufacturer’s instructions. As part of the synthesis 5' 
trityl groups were removed and the oligonucleotides eluted into a solution of 
29% (v/v) ammonia. This eluate was then incubated at 55°C overnight in order to 
de-protect the oligonucleotides. Vials were then chilled on ice and the DNA- 
ammonia solutions transferred to 15 ml Falcon tubes. Oligonucleotides were 
precipitated by the addition of 0.1 volumes of 7.5 M ammonium acetate and 3 
volumes of ethanol, followed by incubation on dry ice for 30 minutes. The DNA 
was then pelleted by centrifugation in a Sorvall HB- 6  rotor at 10,000 g for 15 
minutes. The pellet was washed in 70% (v/v) ethanol, air-dried and dissolved in 
0.5 ml of de-ionised water. DNA concentrations were calculated as described 
below (2.2.2.6) and the oligonucleotides were then stored at -20°C until required.
2.2.2.6 Quantitation of nucleic acid concentrations
Nucleic acids were quantified by spectrophotometric determination of their UV 
light absorbency. Sample aliquots of 5 pi were added to 495 pi of de-ionised 
water and the absorbency of the solution measured at 260 nm and 280 nm in a 
quartz cuvette, using de-ionised water as a blank. The concentration of the 
solution was calculated on the basis that an optical density of 1 .0  at 260 nm 
corresponds to a concentration of 50 pg/ml for double-stranded DNA, 40 pg/ml 
for RNA, and 33 pg/ml for single-stranded oligonucleotides. Pure preparations of 
DNA and RNA have a ratio of A26o/A28o readings between 1.8 and 2.0.
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2.2.3 Polymerase chain reaction (PCR) protocol and product analysis
2.2.3.1 PCR
The following conditions were used to perform the majority of PCR 
amplifications both for allele loss studies and SSCP analysis, but occasional 
slight alterations (to the annealing temperature or concentration of magnesium 
ions) were required to optimise results. 1 0 0  ng of human or mouse genomic 
DNA or 10 pg bacterial clone DNA was subjected to PCR amplification using 
lpM  oligonucleotide primers, 1.5 mM MgCl2, 50pM dNTPs, 1 x reaction buffer 
(50 mM KC1, 10 mM Tris.HCl pH 8.0) and 1 unit Taq polymerase in a total 
reaction volume of 25 pi. 1 pCi [a 32P]-dCTP per reaction was included for in 
situ radiolabelling of amplification products when desired. The thermal cycling 
parameters consisted of 30 rounds of 1 minutes denaturation at 94°C, 30 s 
annealing at 55°C, and 30 s extension at 72°C, using an MJC Research PTC-200 
thermal cycler (Genetic Research Instrumentation Ltd., Dunmow, Essex, UK). 
Following PCR, amplification products were digested where appropriate by 
direct addition of 1 0  units of restriction enzyme without change or modification 
of the buffer and incubated for several hours at the appropriate temperature.
2.2.3.2 Denaturing polyaclylamide gel electrophoresis
Radiolabelled PCR products from amplified polymorphic markers were resolved 
on 6 % (w/v) polyacrylamide gels under denaturing conditions. A gel solution 
was prepared from Sequagel stock solutions which contained 6 % (w/v) 
acrylamide, 0.2% (w/v) bisacrylamide, 1 x TBE, and 8  M urea. The solution was 
polymerised by the addition of 150 pi of 20% (w/v) ammonium persulphate and 
75 pi of TEMED per 60 ml of gel. This solution was then poured between glass 
plates separated by 0.4 mm spacers and was allowed to set at room temperature. 
Gels were pre-run at 100 W for 45 minutes prior to the loading of samples to 
warm the gels to approximately 50°C. 5pl PCR product was mixed with 5 pi of 
STOP buffer (95% formamide, 200mM EDTA pH 8.0, 0.01% (w/v) xylene
cyanol and bromophenol blue) and denatured by heating at 94°C for 10 minutes, 
followed by quenching on ice. 3 pi was then subjected to electrophoresis at 100 
W for 2-3 hr depending upon the size of the PCR product. The plates were then 
separated and the gel transferred to a sheet of Whatman 3MM paper, followed by 
drying under vacuum at 80°C for 45 minutes, prior to detection of PCR products 
by autoradiography using x-ray film in a cassette with intensifying screens at -70 
°C.
2.2.3.3 Tumour allele loss studies
100 ng template DNA was subjected to PCR using the standard reaction 
conditions above (2.2.3.1); amplification products were radiolabelled in situ. 28 
cycles of amplification was taken to be in the linear part of the amplification, 
permitting the assumption that the ratio of the optical densities arising from two 
alleles would be the same for both normal and tumour DNA samples if no LOH 
occurred. PCR products were resolved on 6 % (w/v) polyacrylamide denaturing 
gels and visualised by autoradiography (section 2.2.3.2). Allele loss was 
determined by visual examination of autoradiographs.
2.2.3.4 Non-denaturing polyacrylamide gel electrophoresis
For non-denaturing polyacrylamide gels, a 30 % (w/v) stock solution of 
acrylamide, comprising 29 parts acrylamide to 1 part N,N'methyl-bisacrylamide 
was diluted to give a 6 % (w/v) gel forming solution containing 1 x TBE and 3% 
(v/v) glycerol. This solution was polymerised by the addition of 150 pi of 20% 
(w/v) ammonium persulphate and 75 pi of TEMED per 60 ml of gel. After 
mixing, the solution was poured into vertical plates with 0.4 mm spacing and 
allowed to set at room temperature. 4 pi PCR product was mixed with 8  pi of 
STOP buffer and denatured by heating at 94°C for 10 minutes, followed by 
quenching on ice. 3 pi was then subjected to electrophoresis at a constant 400 V 
for run lengths (of several hours) determined by the migration of the xylene 
cyanol dye front and the size of the PCR product. Gels were fixed by heating at
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80°C under vacuum, and exposed directly to X-ray film for detection by 
autoradiography.
2.2.3.5. SSCP analysis
For SSCP-heteroduplex analysis, 100 ng DNA prepared from tumours or tumour- 
derived cell lines were subjected to PCR using the standard reaction conditions 
above (2.2.3.1). Radiolabelled amplification products were then resolved on 6 % 
(w/v) non-denaturing polyacrylamide gels (section 2.2.3.4) and visualised by 
autoradiography. Electrophoretic mobility shifts in either single or double 
stranded DNA products were visually determined from the autoradiographs.
2.2.3.6 Automated chain terminator sequencing
Both cloned DNA and PCR products were sequenced using a Biosystems ABI 
373A automated DNA sequencer operated as a core service by staff at the BICR. 
0.3-0.5pg of plasmid or 50-100ng of a PCR product was mixed with 20 ng of 
sequencing primer, 8  pi of Dyedeoxy reaction mix in a total reaction volume 
made up to 20 pi with water. DNA was subjected to cycle sequencing in a DNA 
thermal cycler (Perkin Elmer Cetus) for 25 cycles (each cycle comprises 15 s at 
96°C to denature DNA, 1 s at 50°C for annealing, and 4 minutes at 60°C to 
extend), and the products were then ethanol precipitated, washed with 70% (v/v) 
ethanol, and air dried prior to being re-suspended in loading buffer (95% (v/v) 
formamide, 25 mM EDTA pH 8.0, 1.5 mg/ml dextran blue). Samples were then 
denatured by heating at 94°C, chilled on ice, and subjected to electrophoresis as 
advised by the manufacturer. Sequence was analysed using the Sequencing 
Analysis program v3.0.
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2.2.4 Recombinant DNA techniques
2.2.4.1 Restriction digestion of bacterial clone or genomic DNA
Approximately 1 pg of plasmid DNA, 5 pg of cosmid DNA, or 10-20 pg of 
mouse genomic DNA was digested in a final volume sufficient to dilute the 
volume of restriction enzyme added 10-fold. Bacterial clone digests were 
routinely performed using 10 units of enzyme per pg of DNA in each reaction 
and were incubated at the recommended temperature for at least 1 hr. Genomic 
DNA was digested overnight with at least 10 units of enzyme being added for 
each pg of DNA to be digested. A fresh aliquot of enzyme (10 units/pg DNA) 
was added to genomic digests the following morning and the digest continued for 
a further 3 hrs. Digest reactions were stopped by the addition of EDTA to a final 
concentration of 20 mM. Genomic DNA was ethanol precipitated as previously 
described and then air dried prior to being resuspended in an appropriate volume 
of TE for subsequent loading on an agarose gel. For digests of DNA requiring the 
addition of two restriction enzymes, either a buffer compatible for both enzymes 
was selected or the DNA was digested in sequential reactions separated by 
ethanol precipitation.
2.2.4.2 Ligation of DNA/PCR fragments into plasmid DNA
Plasmid DNA was digested as described above. The DNA fragment to be 
inserted was also digested as above to produce blunt ends or complementary 
sticky ends with the vector, and then isolated by gel electrophoresis and purified 
as described in Section 2.2.5.3. To prevent the restricted plasmid DNA from re- 
ligating without an insert, it was first dephosphorylated. Plasmid was digested 
with the required restriction enzyme in the presence of 5 units calf intestinal 
alkaline phosphatase. Enzyme was then removed by extraction with an 
equivalent volume of equilibrated phenol/chloroform, followed by a chloroform 
extraction, and plasmid DNA was then ethanol precipitated. For ligation, 100 ng 
of vector and two times the molar amount of insert DNA were mixed on ice in a 
reaction containing ligase buffer ( 6 6  mM Tris.HCl pH 7.5, 5mM MgC^, 1 mM
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ATP, 1 mM DTT) and T4 DNA ligase (5-10 units), and incubated at room 
temperature for a minimum of 3 hours. PCR products were cloned using a TA- 
cloning kit according to the manufacturer’s instructions.
2.2.4.3 Transformation of bacterial cells with recombinant plasmid DNA
Competent E. coli (DH5a [supEAA A/acU169(cp80 lacZAM15) hsd.RH recAl 
endAl gyrA96 thi-1 relAl], IN V aF [F  supEAA A/acU169(cp80 lacZAM15) 
hsdRYl recAl endAl gyrA96 thi-1 relAl]) were thawed on ice, and aliquots 
transferred to pre-chilled 1.5 ml screw-cap microcentrifuge tubes. Approximately 
10 ng of recombinant plasmid DNA was added to the cells and gently mixed by 
stirring with a pipette tip. After incubation on ice for 30 minutes, cells were heat- 
shocked at 42 °C for 45 s and then placed on ice for a further 2 minutes. 400 [xl 
of SOC medium (2% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 20 
mM glucose, 10 mM NaCl, 10 mM MgCfe) was then added to the mixture and 
the cells were incubated at 37°C for 1 hr in an orbital shaker at 240 rpm. After 
this time cells were pelleted by briefly pulsing in a microcentrifuge, 450 pi of 
supernatant was discarded and the cells resuspended in the remaining 50 pi. Cells 
were then spread on L-broth plates containing 1.5% (w/v) agar supplemented 
with the appropriate antibiotic. Plates were incubated in an inverted position 
overnight at 37 °C.
2.2.4.4 Colony lifts
Hybond N membranes were layered onto plates containing recombinant E. coli 
and left for 1 minute. Five orientation marks were made with a needle through 
the membrane into the agar. After transfer, the filter was carefully lifted ensuring 
not to drag the membrane across the plate, and inverted over 3MM filter paper 
wetted with denaturation solution (1.5 M NaCl, 0.5M NaOH) for 5 minutes, and 
then transferred to 3MM filter paper wetted with neutralisation solution (1.5 M 
NaCl, 0.5M Tris.HCl pH 8.0) for 5 minutes. Finally, the filter was rinsed in 2 x 
SSC, briefly blotted with 3MM filter paper, and UV-crosslinked using a UV
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Stratalinker 1800 (Stratagene). Filters were probed as described below (Section 
2.2.5.5) and exposed overnight to Kodak X-OMAT AR film with intensifying 
screens at -70°C. The films were orientated against the filters using the needle 
marks, and positive clones determined using the strongest signals on the film. 
Plasmid DNA was prepared from positively hybridising colonies as described in 
Section 22.2.2.
2.2.5 Blotting and hybridisation protocols
2.2.5.1 Agarose gel electrophoresis of restriction digested bacterial clone or 
genomic DNA and unlabelled PCR products
DNA restriction fragments from plasmids or genomic DNA or unlabelled (cold) 
PCR products were separated on non-denaturing agarose gels and visualised by 
staining with ethidium bromide and UV transillumination. Typically, gels were 
prepared by dissolving between 1 and 2% electrophoresis grade agarose in 1 x 
TAE (40 mM Tris.HCl pH 8.0, 20 mM sodium acetate, 2 mM EDTA). After 
being heated in a microwave to dissolve the agarose, molten gels were cooled to 
approximately 60°C and ethidium bromide added to a final concentration of 5 
Hg/ml before being poured into an appropriate gel former. Once solid, gels were 
placed into electrophoresis tanks containing 1 x TAE. Samples were mixed with 
one-fifth volume of gel-loading buffer (40% (w/v) sucrose, 0.05% (w/v) 
bromophenol blue and 0.05% (w/v) xylene cyanol) prior to being loaded into the 
wells of the gel. Electrophoresis was performed at 5 V/cm. In order to estimate 
the size of fragments resolved by electrophoresis, samples were run alongside 
aliquots of molecular weight marker, either a Hind ID digest of bacteriophage X 
DNA or an Hae ID digest of bacteriophage <E>X174 DNA. DNA was visualised 
by UV transillumination and the gel photographed.
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2.2.S.2 Purf ication of DNA fragments from agarose gels
DNA bands of interest were excised from agarose gels using a scalpel with the 
aid of UV transillumination. The excised DNA was extracted from the agarose 
using a Geneclean kit according to the manufacturer’s instructions. Excised 
agarose blocks were chopped into small pieces to aid extraction. 2.5 volumes of 
6 M Nal was added and the agarose incubated at 55 °C for 5 minutes to melt the 
gel. Following this, 5 pi of glassmilk was added for every 5 pg, or less, of DNA. 
This was mixed and left at room temperature for 5 minutes to allow binding. The 
glassmilk was pelleted by brief centrifugation and washed 3 times by mixing 
with 300 pi NEW wash (a Tris base and EDTA-buffered solution of NaCl, 
ethanol, and H2O), pelleting the glassmilk and removing the supernatant. Finally, 
half the desired volume of TE was added to the cleaned pellet and heated to 55°C 
for 5 minutes. The glassmilk was pelleted and the TE containing DNA removed 
to a fresh microcentrifuge tube. This was repeated to elute all the DNA. Typically 
for most applications DNA was eluted in a final volume of 20 pi.
2.2.5.3 Preparation of random-primed radiolabeiled probes
The probes used in this study for the analysis of Southern blots are listed in 
appendix 1 .
All probes were radiolabelled with [a 32P]-dCTP via the method of random 
priming using a HighPrime kit. Following each labelling reaction, unincorporated 
nucleotides were removed by spin-column chromatography using MicroSpin S- 
200 HR columns according to the manufacturer’s instructions. Before being used 
in reactions, all double-stranded probes were denatured by addition of an 
equivalent volume of 0.4 M NaOH.
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2.2.5.4 Southern analysis
Following electrophoresis of DNA samples, DNA was depurinated by soaking 
the gel in freshly prepared 0.25M HC1 for 15 minutes at room temperature with 
constant shaking. The gel was rinsed in de-ionised H20 and then soaked for a 
further 15 minutes in 0.4 M NaOH to denature the DNA strands. DNA was 
transferred overnight onto Hybond N+ membrane by capillary blotting using 0.4 
M NaOH, essentially as described in Maniatis et al. (1989).
Membranes were pre-hybridised at 65°C for four hours in hybridisation solution 
(5 X SSPE, 5 X Denhardt’s, 0.5% (w/v) SDS, 1 mg/ml torula yeast RNA type 
VI), and then hybridised overnight at 65°C in a minimal volume of fresh 
hybridisation solution with added radiolabelled probe (5 x 106 cpm/ml). 
Following hybridisation, probe bound non-specifically to the membrane was 
removed by washing the membranes twice in 0.2 x SSC/0.1% (w/v) SDS for 20 
minutes at 65°C, and then once in 0.1 x SSC/0.1% (w/v) SDS for a further 20 
minutes at 65°C. Excess liquid was removed and membranes wrapped in 
Saranwrap before being exposed to X-ray film (X-OMAT-AR, Eastman Kodak 
Co., Rochester, New York, USA) in a cassette with an intensifying screen at - 
70°C for detection of hybridisation by autoradiography.
For successive hybridisations to the same membranes, radiolabelled probe was 
removed from the membranes by washing in a boiling 0.1% (w/v) SDS solution. 
Membranes were then agitated at room temperature until the SDS solution had 
cooled to room temperature. Blots were then wrapped in Saranwrap and stored at 
4°C until further required.
2.2.6 cDNA library screening
A fetal mouse brain cDNA library constructed in the ZAP II vector was 
purchased from Stratagene. Plating and screening of the library was carried out 
essentially as described in the Stratagene instruction manual, summarised below.
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2.2.6.1 Titering phage
The Lambda ZAP II phage was diluted in 4 serial 10-fold dilutions in SM buffer 
(10 mM MgSC>4, 50 mM Tris.HCl pH 7.5, 10 mM NaCl, 0.01% (w/v) gelatin). In 
a 15 ml sterile tube, 600 pi of XLl-blue cells diluted to OD6oo = 0.5 were mixed 
with 1 pi of each Lambda phage dilution and incubated at 37°C for 15 minutes to 
allow the phage to attach to the cells. 8  ml molten top agar (0.7% (w/v) agarose 
in L-broth cooled to 50°C) was added to the culture-phage mix and poured 
immediately onto warmed (37 °C) 140 mm L-broth plates. The plates were left to 
set at room temperature and then incubated at 37°C overnight. The number of 
plaques per plate were counted and the titre calculated using the formula:
titre = (no. plaques x 1 0 0 0  x dilution factor) pfu/ml.
2.2.6.2 Screening cDNA library
Approximately 150,000 pfu were plated on each of four large 245mm square L- 
broth plates with 2 ml of OD600 = 0.5 XL 1-Blue cells/plate and 30m l top 
agar/plate. These were incubated overnight at 37°C. The plates were refrigerated 
for 2 hours at 4°C prior to taking lifts, as this prevents the top agar from sticking 
to the nitrocellulose filter. Filters were prehybridised, hybridised and washed as 
described in section 2.2.5.4. They were then wrapped in Saranwrap and exposed 
overnight to Kodak X-OMAT AR film with intensifying screens at -70°C. The 
films were orientated against the filters using the needle marks, and positive 
clones determined using the strongest signals on the film. The end of an inverted 
pasteur pipette was used to core the putative clones from the stock agar plates, 
and the agar plug placed into an microcentrifuge tube with 500 pi SM buffer and 
20 pi chloroform. The tube was briefly vortexed and incubated overnight at 4°C 
to elute the phage. The phage stock is stable for 1 year at 4°C.
For each positive clone, 1 pi of a 200-fold dilution of eluted phage in SM buffer 
was added to 600pl XLl-Blue cells at OD600 = 0.5, incubated at 37°C for 15 
minutes, mixed with 8  ml molten top agar, and poured onto 140 mm L-broth
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plates. Transfer to nitrocellulose filters and screening was carried out as 
described above. This procedure was repeated for a maximum of three platings, 
such that single positive plaques were isolated.
2.2.6.3 In  vivo excision of the pBluescript phagemid
In vivo excision of the cloned insert is dependent upon the simultaneous infection 
of XLl-blue cells with both the lambda vector (containing cloned insert) and the 
M13 helper phage (ExAssist). For a full description of this, see the Stratagene 
manual.
Single plaques, isolated as described above, were placed in 500 pi SM buffer 
with 20 pi chloroform and incubated overnight at 4 °C. In a 15 ml conical tube 
200 pi of OD600 = 1.0 XLl-Blue cells, prepared as in section 2.2.6.1, were 
combined with 100 pi eluted phage stock and lu l ExAssist helper phage, and 
incubated at 37°C for 15 minutes. After which, 3 ml of terrific broth (for 1 litre: 
12g bacto tryptone, 24g bacto yeast extract, 4m l glycerol. After autoclaving add 
100 ml solution B (0.17 M KH2P 0 4, 0.72 M K2H P04 }) was added and 
incubated at 37°C with shaking for 2Vi hours. The tube was heated at 70°C for 15 
minutes, and centrifuged for 5 minutes at 4000g. The supernatant containing the 
pBluescript phagemid, packaged as phage particles, was stored at 4°C.
To rescue the phagemid, 1 pi supernatant from above was added to 200 pi OD600 
= 1.0 SOLR host cells, and incubated at 37°C for 15 minutes. Following 
incubation, 10 pi and 100 pi of the phage/SOLR mix was spread onto L-broth 
plates containing 50 pg/ml ampicillin, and incubated overnight at 37 °C. 
Minipreparations of plasmid DNA were prepared as described in section 2.22.2.
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2.2.7 Fluorescent in situ hybridisation
2.2.7.1 Preparation of metaphase spreads
Established cell lines were cultured until subconfluent, at which time they were 
treated with colcemid (0.01 pi /ml) for 2-3 hours at 37°C, and then harvested. 
The cells were centrifuged at 1500rpm for 5 minutes. Most of the supernatant 
was removed and the cells were resuspended in the residual medium. Pre­
warmed hypotonic buffer (0.075M KCI, 37°C) was added dropwise. The cells 
were incubated at 37°C for 5-10 minutes, then centrifuged at 1500 rpm for 5 
minutes. Most of the supernatant was removed and the cells again resuspended 
in the remaining buffer. The swollen cells were then fixed in 3:1 methanol/acetic 
acid and left at room temperature for 15 minutes, followed by centrifugation at 
1500rpm for 5 minutes, to remove the supernatant. Fixation was repeated twice. 
The cells were dropped from a height on to clean, moist slides and immediately 
washed in 3:1 methanol/acetic acid.
2.2.7.2 Preparation of probes
FITC-labelled whole mouse chromosome paints were purchased from Cambio. 
For each slide, lOpl of probe was denatured at 75°C for 5 minutes, and incubated 
at 37°C for 30 minutes to allow for pre-annealing of CGtl repetitive DNA prior to 
applying to metaphase chromosomes.
2.2.13 In situ hybridisation
Metaphase spreads were fixed in 3:1 methanol / acetic acid for 1 hour, rinsed in 2 
x SSC, and then treated with RNase (lOOg/ml) in 2 x SSC at 37°C for 1 hour. 
Slides were rinsed in 2 x SSC, then treated with 0.01% pepsin in 0.01M HCI at 
37°C for 10 minutes. After rinsing in phosphate buffered saline (PBS) and fixing 
in Streck Tissue Fixative for 10 minutes at room temperature, the chromosomes 
were dehydrated in 70% and 100% ethanol.
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Chromosomes were denatured prior to thin hybridisation in 70% formamide in 2 
x SSC at 80°C for 3 minutes. Slides were quenched in ice-cold 70% ethanol, then 
dehydrated. The probe was applied to the denatured chromosomes, and 
hybridisation was carried out under a sealed coverslip at 37°C overnight in a 
humidified chamber.
After hybridisation, coverslips were removed in 2 x SSC and slides were washed 
in 50% formamide/1 x SSC and then 2 x SSC, both at 42°C for 20 minutes each. 
Metaphase spreads were washed for 10 minutes in 4 x SSC-T and then 
dehydrated in 70% and 100% ethanol, and mounted in anti-fade medium 
(Vectashield, Vector Labs) containing 0.1 pg/ml DAPI and 0.34g/ml PI. The 
mouse whole chromosome paints were directly labelled with FITC. Therefore, 
following the wash steps in 50% formamide and 2xSSC, slides were dehydrated 
in 70% and 100% ethanol, and mounted in anti-fade medium containing DAPI 
and PI as before. Fluorescence was analysed using a BioRad MRC-600 laser 
scanning confocal microscope equipped with a krypton argon ion laser, using 
488/568nm line excitation, and dual channel 522nm and 585nm filters.
Chromosome copy numbers were obtained by analysing a minimum of 20 
metaphase spreads per cell line. Total numbers of chromosomes were derived 
from the mean of 10 individual metaphase spreads.
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CHAPTER 3
RESULTS
LOSS OF 
HETEROZYGOSITY 
STUDIES
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3. Results
3.1 Loss of Heterozygosity Analysis in Mouse Skin Tumours
Previous work by Zenklusen and colleagues had demonstrated a high freqency of 
allele loss on mouse chromosome 6, band A2 in both the murine skin and 
hepatoma carcinogenesis models (Zenklusen et al. 1996b, 1997), suggesting the 
presence of one or more tumour suppressor genes in this area. I chose initially to 
confirm these observations and to extend them by saturating the area of interest 
with microsatellite markers obtained from the public databases. In so doing I 
aimed to define a smallest common deleted region (SCDR).
The use of interstrain and interspecific F I hybrid mice greatly facilitates 
polymorphic microsatellite analysis since the likelihood of length polymorphism 
and therefore informativeness is high. This is particularly so in the case of 
interspecific crosses. With this in mind, over thirty microsatellite repeats of the 
simple (CA)n variety spanning the first 8 cM of mch6 (the area of highest loss in 
previous studies) were examined for length polymorphisms in the following 
strains of mice: M. spretus, NIH/Swiss, SENCAR, BALB/c, B6, FVB and 129. 
As expected, the highest degree of informativeness was between M. musculus 
strains and M. spretus. Figure 3.1 demonstrates simple sequence length 
ploymorphisms (SSLP) between strains. Using the 21 informative markers 
identified in this way, I then searched for allele loss in papillomas and 
carcinomas induced in NIH x Spretus F I (10 papillomas, 17 carcinomas), 129 x 
NIH FI (15 carcinoma, 6 papilloma) and SENCAR x Balb (5 carcinoma, 2 
papilloma) F I mice. A total of 55 cases were examined, consisting of 18 
papillomas and 37 carcinomas. Tumours had been induced and harvested in 
house, and had been gifted to me by Professor A. Balmain. Naturally not all 
markers were informative for all hybrids. Figure 3.2 shows representative 
autoradiographs of PCR amplified microsatellite repeats demonstrating LOH and 
tables 1, 2 and 3 show the pattern of losses seen within each of the three crosses.
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6-166
6-296
6-83
6-236
6-167
6-170
6-158
6-89
Table 3.3. Loss of heterozgosity in papilloma (p) and carcinoma (c) 
tumours derived from SENCAR x Balb/c mice. Tumour cases are shown 
on the x-axis while microsatellite markers, ordered acromeric to 
telomeric, are shown on the y-axis. Loss of heterozygosity is denoted by 
filled boxes.
A moderate frequency of allele loss seems to be common in the region examined 
(summarised in table 3.4). The highest frequency of loss is seen at markers 
D6mit236 (3.1cM from the acromeric tip of mchr6) and D6mitl66 (0.6cM), 
although in the latter case the total number of tumours examined is small. These 
markers are found on mchr6 region A2, a region syntenic with human 
chromosome 7q31.1-2. The most distant marker, D6mit29 on mchr 6A3, also 
showed moderately high incidence of loss (26%), although to date synteny has 
not been established to any human chromosome.
Table 3.4 Summary of tumour loss of heterozygosity data. Microsatellite markers are ordered 
from acromeric to telomeric
Marker cM Loss in papillomas Loss in carcinomas total (%)
D6Mit86
Position
™0.5 2/10 4/17 22
D6M tl66 0.6 1/2 1/5 29
D6Mit296 0.625 0/2 0/5 0
D6M itl38 0.65 3/10 4/17 26
D6Mit83 2.7 0/8 0/28 0
D6Mit305 2.8 1/10 0/17 4
D6Mit236 3.1 7/18 10/37 33
D6Mit264 3.2 0/10 2/17 7
D6Mit347 3.2 0/10 2/17 7
D6Mit50 3.3 1/6 0/15 5
D6M itl67 3.4 2/8 2/20 14
D6Mit221 3.5 3/10 4/17 26
D6Mit232 3.5 0/10 0/17 0
D6Mit233 3.5 0/10 2/17 7
D6Mit235 3.5 0/10 2/17 7
D6M itl70 4.0 1/12 2/22 9
D6M itl58 6.0 1/12 5/22 18
D6Mit297 6.0 1/10 4/17 18
D6Mit89 7.0 1/18 4/37 9
D6Mit29 30.0 1/10 6/17 26
Looking at the pattern of losses in different crosses, it is difficult to draw firm 
conclusions as to the existence of a SCDR. This is particularly so in the case of 
the Spretus x NIH cross. Three out of 27 cases show isolated loss of 
heterozygosity at marker D6Mit236, but the same could be said of other markers 
at different areas. The Spretus x 129 and Senear x Balb F I tumours are more 
helpful: losses do seem to be centred around marker D6Mit236 and this could 
potentially represent a SCDR. Loss of heterozygosity throughout the region
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examined was not confined to carcinomas; both papillomas and carcinomas were 
involved in roughly equal proportions.
3.2 Analysis of Cell Lines
3.2.1 Molecular analysis of cell lines
I examined the panel of cell lines in my possession for allele loss. These cell 
lines are representative of the various sequential steps in mouse skin 
carcinogenesis (see Materials and Methods 2.1.13 for a full description of 
origin). Some of these lines were derived from interspecific F I crosses, and 
therefore lent themselves to classical LOH analysis. Others were from individual 
mouse strains which, although not amenable to LOH analysis, would still 
demonstrate homozygous deletion at a locus if present. Clearly this would be 
very helpful in attempting to localise any putative tumour suppressor gene, since 
it implies a small and specific deletion.
No homozygous loss was apparent at any marker locus. Indeed no absolute loss 
of heterozygosity was detectable in any cell line. As demonstrated by previous 
investigators (Kemp et al., 1993b), there was evidence of allelic imbalance 
(figure 3.3). This was likely to be indicative of aneuploidy, since it has been 
established that a number of the cell lines are tri- or tetrasomic for mouse 
chromosome 6. The cell lines I had examined and which showed allelic 
imbalance had not hitherto been analysed for ploidy. I therefore decided to 
establish the copy number of chromosome 6 using whole chromosome painting.
3.2.2 FISH analysis of cell lines
Chromosome painting is a specific application of fluorescent in-situ hybridisation 
(FISH) technology which allows direct visualisation of specific chromosomes in 
metaphase spreads and interphase cells. The paints themselves represent a large 
collection of DNA probes generated by fluorescently-labelled PCR from a single 
chromosome which hybridise to the entire length of the corresponding
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chromosome (Rabbitts et al., 1995). In addition to allowing determination of 
chromosome copy number, paints have found widespread application in defining 
de novo chromosome rearrangements in clinical genetics and cancer cytogenetics 
(Trask, 1992; Ried et al., 1998).
I examined the copy number of mouse chromosome 6 (and, in a smaller number 
of cases chromosome 15), in cell lines representing the stages in mouse skin 
cancer progression. Described briefly, C50 is an immortal, non-tumorogenic line; 
MSCP is derived from a papilloma; E4 is from a squamous explant; and carB 
and H l l  are derived from highly aggressive spindle cell cancers. Chromosome 
15 was chosen as a control because, in contrast to chromosome 6, it is not known 
to harbour any genes involved in skin cancer progression. Table 3.5 shows 
representative numbers from the FISH analyses, and figures 3.4 and 3.5 
representative chromosome spreads.
Table 3.5 Summary of FISH analysis on mouse cell lines using whole chromosome paints 
specific to mouse chromosomes 6 and 15
Cell Line Chromosome 6 Chromosome 15 Total chromosome 
number
Macrophage* 2 - 40
C50 4 4 65
MSCP 3 - 62
E4 3 2 63
Car B 3 - 62
H ll 3 4 69
* Data not shown
All the cell lines examined possessed more than two copies of chromosome 6, 
helping to explain the finding of allelic imbalance. The cell line C50, an 
immortal, non-tumorogenic line often taken as representative of the normal 
keratinocyte, would appear from the point of view of chromosome number to be 
anything but this. In fact the cells are near-tetraploid, an observation also made of 
a related non-tumorigenic line, C5N (S. Frame, unpublished).
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Figure 3.4. Examples of chromosome painting using fluorescently-labelled whole 
chromosome paints. A, E4 cells using chromosome 6 paint; B, MSCP cells using 
chromosome 6 paint.
Figure 3.5. Examples of chromosome painting using tluorescently-labelled whole 
chromosome paints. A, C 50 cells using chromosome 6 paint; B, HI 1 cells using 
chromosome 15 paint.
3.2.3 Southern blot analysis of candidate TSGs in cell lines
The ability to use information on a potentially homologous gene in human 
epithelial cancer is a boon of this project: mapping information from work on 
human chromosome 7 should facilitate the search for the putative TSG in mouse, 
and vice versa. Data generated within our laboratory on human candidate genes 
were used to look for homozygous deletions at the homologous loci in the mouse 
cell lines. The two human candidate genes which showed the most promise as 
tumour suppressor genes were caveolin-1 and a novel member of the kelch gene 
family, as yet unnamed.
In the case of caveolin-1, a 700bp probe derived from the coding region of the 
human sequence was hybridised directly to Southern blots prepared from mouse 
cell lines, since homology was expected to be high between the two species. 
With the novel kelch gene, an 800bp probe was generated from a mouse foetal 
brain cDNA library using primers derived from mouse ESTs that matched the 
cloned human kelch cDNA sequence. As a positive control, the Southern blots 
were probed with a mouse H-ras probe. The blots and corresponding gel are 
shown in figures 3.6 and 3.7. As can be seen, no homozygous deletions were 
discovered.
3.3 Summary of Allelotyping Data
A moderate degree of LOH is present at mouse chromosome 6A2 and the SCDR 
may be centred on marker D6mit236. Figure 3.8 shows the position of marker 
D6mit236 in the context of a gene map of the region, and also demonstrates 
established synteny with human chromosome 7. The marker D6mit236 has now 
been mapped to an exonic region of the murine cftr gene. Interestingly, the 
SCDR in LOH studies examining human breast tumours maps to intron 17b of 
the CFTR gene (A. Hurlstone, unpublished).
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Sizes
C50 P A5 Bi; Di H ll cB cC T <1>X XHind
2 3 1 3 0 b p
9 4 1 6  b p  
6 3 5 7 bp
13 5 3 b p  
1 0 7 8 b p  
8 7 2 b p
6 0 3  b p
Figure 3.6. Photograph of mouse cell line DNAs (5gg per lane) digested with Bam 
H l/E coR  1 and run on an agarose gel. Size markers are identified to the right.
A('50 P AS BO D3 H ll carR carC 1
n r - : 
* § ■
« • -
t - t  1 1
B
C50 P AS BO D3 H ll carB cart’ 1
c
( ’50 P AS BO D3 H ll carB cart’ I
Figure 3.7. Southern blot analysis of cell lines. The blot corresponds to the 
gel shown in figure 3.6. A is probed with H-ras as a positive control. Note 
the (expected) presence of mutant \\-ras  in some cell lines (vertical arrows). 
B is probed with kelch  related gene, and C is probed with caveolin-1 .
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Figure 3.8. Representation of mouse chromosome 6 showing positions of a number of 
microsatellite markers and genes. Also shown are approximate stretches of known synteny 
with human chromosome 7.
* D6mit50 (~6cM) represents the SCDR as defined by Zenklusen et al., 1996. This marker 
has recently been re-ordered, and is now situated at 3.3cM.
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4. Results
4.1 Cloning of Candidate Genes
Generation of candidate genes that can be examined for mutations in tissues of 
interest is an integral part of the positional candidate gene approach. In an effort to 
identify the human putative tumour suppressor gene from human chromosome 7q31, 
a number of genes were identified from a human senescent fibroblast library which 
mapped to the area of interest. As already stated, an advantage of this project is that 
data generated from human studies can expedite a search for the mouse ortholog, 
and vice versa. Full use has therefore been made of information on potential human 
candidates, and several of these were cloned in the mouse and subsequently screened 
for mutations in the mouse skin carcinogenesis model. The cloning of three such 
genes is described.
An overall schema showing the steps involved in isolating genes of interest from a 
cDNA phagemid library is shown in figure 4.1. Bacteriophage infected host bacteria 
are poured over agar plates and incubated for several hours, allowing plaques to 
appear on a bacterial ‘lawn’. Plaques are lifted onto a nitrocellulose filter, denatured, 
washed and dried. The DNA is fixed to the membrane by exposure to UV light. A 
radiolabelled probe is then applied to the membrane lifts in hybridisation buffer, the 
filters are washed and exposed to photographic film to obtain an autoradiograph. 
From the Xray film, positive colonies are identified and isolated. The process is 
repeated twice to obtain positive secondary and tertiary clones. The isolated positive 
tertiary clones are then grown in liquid culture, the DNA isolated and finally 
analysed.
4.2 Putative cyclin G1 binding protein
One of the genes isolated from a human senescent fibroblast cDNA library (by 
virtue of its being upregulated) and which mapped to the human region of interest
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was a putative cyclin G1 binding protein. It is known from information in public 
databases to map to the human region 7q22-31 and, since a high degree of synteny is 
observed between 7q and mouse 6A, it is expected to map to the area of high 
frequency LOH in the mouse skin carcinogenesis system. It therefore qualifies 
tentatively as a potential candidate gene.
A search of the mouse EST databases was undertaken using the full-length human 
cDNA sequence and, from homologous hits, primers were designed to amplify a 
~300bp fragment to be used as a probe. Figure 4.2A shows the PCR product using 
these primers with cDNA prepared from a mouse keratinocyte cell line (C5N) and 
genomic (tail) DNA as template. As can be seen the PCR product from genomic 
DNA is significantly larger than that from the cDNA template, implying the 
presence of an intron. The 300bp fragment was excised, radiolabelled and used to 
probe a mouse fetal cDNA library. Figure 4.2B shows the autoradiograph of the 
primary filter. Figure 4.3A shows an autoradiograph of the secondary filter obtained 
after plating one of the chosen clones arrowed in figure 4.2B. Two clones were then 
isolated, and figure 4.3B shows the insert size of both after excision from vector and 
resolution on an agarose gel. Both clones were sequenced and the resulting sequence 
used to search the mouse EST database for homologies using the blast protocol 
(Altschul et al., 1997). Both sequences in fact corresponded to the mouse putative 
cyclin G1 bindng protein. Clone 2 was however more complete, spanning the start 
and stop codons.
Figures 4.4 and 4.5 show the complete DNA coding region of the mouse putative 
cyclin G1 binding protein and its degree of homology to the human sequence at the 
DNA and protein levels. As might be expected the level of homology between man 
and mouse is high: 88% at the nucleic acid level, and 78% at the amino acid level.
I next looked for evidence of mutations by single strand conformational 
polymorphism (SSCP) in the cloned gene in the panel of mouse cell lines 
representative of the multiple stages in skin carcinogenesis. SSCP is a relatively
80
Figure 4.2. A, PCR product used to probe the primary filter o f  a mouse foetal brain cDNA 
library. Lanes are numbered 1-4: 1 and 2 are identical, as are 3 and 4. This was to ensure high 
yield of DNA for radiolabelling. Template for PCRs 1 and 2 is C5N cDNA, and for 3 and 4, 
genomic (tail) DNA. Marker sixes are shown in bp to the left. The ~3()()bp product was 
excised from the agarose gel and genecleaned before use. B, picture (60% lifesize) ot 
autoradiograph from primary filter probed with radiolabelled probe shown in A. The clones 
chosen to be plated onto secondary plates are arrowed.
Figure 4.3. A, autoradiograph of secondary filter of eg 1 bp clones reprobed 
with the original PCR product shown in figure 1. B, excised inserts of two 
clones shown in A, after resolution on an agarose gel. Size markers are on the 
left.
Accaatggtggagaagaaacccgccgttcgctcacaggaccctggacagcggcgggtgctg 
M V E K K P A V R S Q D P G Q R R V L  
gacagggcagccaggcagcggcggatcaaccgacagctggaggcattggagaatgacaac 
D R A A R Q R R I N R Q L E A L E N D N  
ttccaggatgacccccatgccggcctcccccagctgggcaagaggctacctcagtttgat 
F Q D D P H A G L P Q L G K R L P Q F D  
gatgatgcagacacaggaaagaaaaagaagaaaactcgaggtgaccactttaaacttcgc 
D D A D T G K K K K K T R G D H F K L R  
ttccggaaaaacttccaggctttgctggaggagcagaacctgagtgcatctgagggcccc 
F R K N F Q A L L E E Q N L S A S E G P  
aaccactcgacagcctgtgccggccccccatctcggccccagcgtcccttctgtgctgtg 
N Y L T A C A G P P S R P Q R P F C A V  
tgtggcttcccatccccgtatacctgtgtgagctgtggtgcccggtactgcaccgtgcgc 
C G F P S P Y T C V S C G A R Y C T V R  
tgcctgggtacccatcaggagaccaggtgtctgaagtggaccgtgtaaacctggcatcag 
C L G T H Q E T R C L K W T V  STOP 
ggagagaaagtacccccacccttcccaacccaccccagctcat
B
M o u s e : 1
H um an: 1
M o u s e : 61
H um an: 61
M o u s e : 12:
H um an: 12
MVEKKPAVRSQDPGXXXXXXXXXXXXXINRQLEALENDNFQDDPHAGLPQLGKRLPQFXX 6 0 
MVEKK +VRSQDPG INRQLEALENDNFQDDPHAGLPQLGKRLPQF
MVEKKTSVRSQDPGQRRVLDRAARQRRINRQLEALENDNFQDDPHAGLPQLGKRLPQFDD 6 0
XXXXXXXXXXXXXXHFKLRFRKNFQALLEEQNLSASEGPNYLTACAGPPSRPQRPFCAVC 12( 
HFKLRFRKNFQALLEEQNLS +EGPNYLTACAGPPSRPQRPFCAVC
DADTGKKKKKTRGDHFKLRFRKNFQALLEEQNLSVAEGPNYLTACAGPPSRPQRPFCAVC 1 2 i
GF P S PYTCVSCGARYCTVRCLGT HQETRC LKWTV 15 4  
GF P S PYTCVS CGARYCTVR CLGTHQETRC LKWTV
Figure 4.4. A, complete coding sequence and translation of the mouse putative 
cyclin G1 binding protein. B. homology at the protein level between mouse and 
human sequences. The consensus is highlighted.
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Mouse: 3 ccaatggtggagaagaaacccgccgttcgctcacaggaccctggacagcggcgggtgctg 62
I I I I I I I  I I  I I I I I I I I I I I l l l l l l l l  M I N I M  I I  I I I I I I I I I I I I I I I
Human: 28 ccaatggtggagaagaaaacttcggttcgctcccaggaccccgggcagcggcgggtgctg 87 
Mouse: 63 gacagggcagccaggcagcggcggatcaaccgacagctggaggcattggagaatgacaac 122
I I I  M I I  I I I  1 1 I I 1 1 1  I I  l l l l l l l l  I I 1 1 1 1 1 1 1 1 1  1 1 1 1 1 1 1 1 1 1 1 I I I
Human: 88 gaccgggctgcccggcagcgtcgcatcaaccggcagctggaggccctggagaatgacaac 147 
Mouse: 123 ttccaggatgacccccatgccggcctcccccagctgggcaagaggctacctcagtttgat 182
I I I I I I I I I I I I I I I  I I I I  I I  M i l l  M i l l  l l l l l l l l  I I  I I I I I I I I I I I I
Human: 148 ttccaggatgacccccacgcgggactccctcagctcggcaagagactgcctcagtttgat 207 
Mouse: 183 gatgatgcagacacaggaaagaaaaagaagaaaactcgaggtgaccactttaaacttcgc 242
I I  M i l l  M i l l  I I I I I I I I I I 1 1 1 1 1 1 1 1 1 1  l l l l l l l l  I I  1 1 1 1 1 1 1 1 1 1 1 1
Human: 208 gacgatgcggacactggaaagaaaaagaagaaaacccgaggtgatcattttaaacttcgc 267 
Mouse: 243 ttccggaaaaacttccaggctttgctggaggagcagaacctgagtgcatctgagggcccc 3 02
h i m  i i i i i i i i  h i m  i i  11111i i 1111i i i  l i n n  i i i i i i i i i
Human: 268 ttccgaaaaaactttcaggccctgttggaggagcagaacttgagtgtggccgagggccct 327 
Mouse: 303 aactacttgacagcctgtgccggccccccatctcggccccagcgtcccttctgtgctgtg 362
M i l l !  1 1 1 1  l l l l l l l l  I I  l l l l l l l l  1 1 1 1 1 1 1 1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1
Human: 328 aactacctgacggcctgtgcgggacccccatcgcggccccagcgccccttctgtgctgtc 387 
Mouse: 363 tgtggcttcccatccccgtatacctgtgtgagctgtggtgcccggtactgcaccgtgcgc 422
I I I I  I I  I I  I I I  I I I I I  I I I  l l l l l l l l  M i l l  I I  I I I I I I  I I I I I  I I I I l l l l l l
Human: 388 tgtggcttcccatccccctacacctgtgtcagctgcggtgcccggtactgcactgtgcgc 447 
Mouse: 423 tgcctgggtacccatcaggagaccaggtgtctgaagtggaccgtgtaa 470
I I  M i l l  M i l l  1 1 I I I I 1 1 1 I I I I I I 1 1 1 I I I I I I I I  1 1 1 1  I
Human: 448 tgtctggggacccaccaggagaccaggtgtctgaagtggactgtgtga 495
Figure 4.5. cDNA sequence comparison between the mouse and human 
putative cyclin G1 binding protein
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Single
stranded
DNA
Double
stranded
DNA
>
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Figure 4.6. SSCP analysis of putative cyclin G1 binding protein in mouse cell 
lines. The gene was analysed in two regions, 5 ’ and 3 ’ products. Lanes are 
marked 1-12, corresponding to the following cell lines: 1, C5N; 2, C50; 3, 
M SCP1; 4, B9; 5, A 3 ; 6, D3; 7, CarB; X, CarC; 9, S N 161; 10, E4; 11, HI 1; 12, 
PDV
simple technique which allows rapid screening of DNA samples for mutations or 
deletions with an acceptable level (~80%) of sensitivity. The technique is predicated 
on the fact that electrophoretic mobility of single stranded DNA is dependent not 
only on length but also on conformation, which is in turn dictated by sequence. As 
originally described, the technique involved digestion of genomic DNA prior to 
running on a neutral polyacrylamide gel. However, the technique can be applied 
equally well to PCR amplified genomic DNA and, as in this study, cDNAs created 
by the RT-PCR method. The optimum length of sequence for analysis is ~200bp, but 
100-300bp fragments are acceptable.
The SSCP gels are shown in figure 4.6. As can be seen, no sequence variants were 
detected by SSCP.
4.3 Novel kelch Gene
The second human candidate gene, once more identified from a human senescence 
library by virtue of its upregulation, appeared to be a novel homologue of the 
Drosophila kelch gene (Xue and Cooley, 1993). Again, it mapped to the long arm of 
human chromosome 7.
Human cDNA sequence was used to identify mouse ESTs from the public database, 
from which primers were designed to generate an 800bp mouse probe. Figure 4.7 
shows the PCR product which was radiolabelled and used to probe the mouse cDNA 
library, along with the autoradiograph of the primary filter. Figure 4.8 shows 
examples of the corresponding secondary and tertiary filters. A total of five clones 
were isolated and sequenced to ensure complete coverage of the mouse kelch coding 
region. PCRs using a variety of primers designed from mouse ESTs and compared 
to the known human sequence are shown in figure 4.9. This provided a rapid method 
of “sequencing” the clones. The entire cDNA and amino acid sequences are shown 
in figure 4.10, and figure 4.11 depicts the positions of the conserved protein domains 
as predicted by the blastp search protocol. Homology to the human kelch related
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Figure 4.7. A, Kelch probe (arrowed) generated using PCR primers designed from 
mouse ESTs found to be homologous to the human kelch  sequence. The probe was 
excised and genecleaned before use. Size markers are identified on the left. B, 
autoradiograph of primary filter probed with the radiolabelled PCR product shown in A.
BFigure 4.8. A and B, autoradiographs of a secondary and tertiary filter, respectively, of 
mouse kelch clones isolated from the primary filter shown in figure 4.7. wSeveral secondary 
and related tertiary plates were produced, from which a total of five clones were isolated
C lo n e  1 C lo n e  2 C lo n e  3
C lo n e  4 C lo n e  5 Insert size  o f  c lo n es  1 -5
Figure 4.9 A, p r im ers  w e re  d e s ig n ed  from  m o u se  E S T s  c o r re sp o n d in g  to the  h u m an  kelch re la ted  
g ene ,  and used to am p l i fy  the m o u se  c lones.  T h e ir  ap p ro x im a te  re la t ive  p o s i t ions  are sh o w n .  B, 
P C R  am plif icat ion  p ro d u c ts  c o r re sp o n d in g  to the five m o u se  c lones.  Fa i lu re  to am p l i fy  im plies  
a b sen ce  o f  re la ted  sequence .  Also show n  is the  insert size o f  each c lo n e  us ing  SK  and  KS p r im ers  
w h ic h  b o u n d  the p o ly l inke r  site. T h e  apparen t  band  co r re sp o n d in g  to p roduc t  5-6  f rom  c lo n e  4 is 
ar te fac tual .  T h e  5 F -6 R  p r im er  c o m b in a t io n  co n s is ten t ly  failed to amplify .
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K L I A A G G Y N R E E C L R T V E C Y  
g a t c c a c a t a c a g a t c a c t g g t c c t t c c t t g c t c c c a t g a g a a c a c c a a g a g c c c g c t t t  
D P H T D H W S F L A P M R T P R A R F  
c a a a t g g c t g t g c t g a t g g g a c a g c t c t a tg t g g t g g g tg g a tc a a a tg g a c a c t c a g a t  
Q M A V L M G Q L Y V V G G S N G H S D  
g a c c t g a g t t g t g g a g a a a t g t a t g a t c c a a a c a t t g a t g a c t g g a c c c c t g t t c c a g a g  
D L S C G E M Y D P N I D D W T P V P E
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c t g a g a a c c a a c c g t t g t a a t g c a g g a g t g t g t g c t c t g a a t g g g a a a t t g t a c a t t g t t  
L R T N R C N A G V C A L N G K L Y I V  
g g t g g c t c t g a t c c a t a t g g t c a a a a g g g c c t g a a a a a t t g t g a t g t a t t t g a t c c t g t a  
G G S D P Y G Q K G L K N C D V F D P V  
a c g a a g t c a t g g a c a a g c t g t g c t c c t c t t a a c a t t c g t c g a c a c c a g t c t g c a g t t t g t  
T K S W T S C A P L N I R R H Q S A V C  
g a a c t t g g t g g t t a t t t g t a t a t a a t t g a a g g t g c a g a a t c t t g g a a t t g t c t g a a c a c a  
E L G G Y L Y I  I E G A E S W N C L N T  
g ta g a a c g a t a c a a t c c tg a a a a c a a c a c c t g g a c t t t a a t t g c a c c c a tg a a t g t g g c g  
V E R Y N P E N N T W T L  I A P M N V A  
a g g c g a g g g g c t g g a g t c g c t g tg c t tg a tg g a a a a c t g t t t g t a g g t g g tg g c t t t g a t  
R R G A G V A V L D G K L F V G G G F D  
g g t t c t c a c g c c a t c a g t t g t g t g g a g a t g t a t g a t c c a a c t a g a a a t g a a t g g a a g a t g  
G S H A I S C V E M Y D P T R N E W K M  
a tg g g a a a ta tg a c t t c a c c a a g g a g c a a tg c tg g g a tc a c a a c tg t a g g g a a t a c c a t t  
M G N M T S P R S N A G I T T V G N T  I  
t a t g c a g t g g g a g g a t t c g a t g g c a a t g a g t t t c t g a a t a c t g t g g a a g t c t a c a a c c c t  
Y A V G G F D G N E F L N T V E V Y N P  
c a g t c a a a t g a g t g g a g c c c t t a c a c a a a g a t t t t c c a g t t t t a a c a a a t t t a a g a a c c c  
Q S N E W S P Y T K I F Q F  STOP  
c a a a c t a a c a g g c t t a g t g a t g t a a t t s t c g t t t a g t a g a g g t c a c t t g t g a a t a a g g a g  
g g t g g g t g g g g t a a g a t g t t g c t a a c c t g c a a c a c c a a g c t t t t g c a t a t t g c t t a t t a t  
t a a a c a t g c t g g c c a t a c t t t t t g g g g t t g g a a t g g a a t g c a a a g a t g a a a g g t c t g g t t  
t c t g g a t t t t t t a a a a c a t c t t t g g g t a t t t t a c c t t t t t
Figure 4.10. Complete coding sequence of the novel kelch gene, with protein 
tranalation.
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A6t» 642
Kelch Kelch IESEHSEIEHM
B
repeat from to fragment
KELCH 369 415 KLIAAGGYNREECLRTVECYDPHTDHWSFLAPMRTPRARFQMAVLMG
KELCH 416 463 QLYWGGSNGHSDDLSCGEMYDPNIDDWTPVPELRTNRCNAGVCALNG
KELCH 465 512 LYIVGGSDPYGQKGLKNCDVFDPVTKSWTSCAPLNIRRHQSAVCELGG
KELCH 514 559 LYIIEGAESWNCLNTVERYNPENNTWTL1APMNVARRGAGVAVLDG
KELCH 560 606 KLFVGGGFDGSHAISCVEMYDPTRNEWKMMGNMTSPRSNAGITTVGN
KELCH 608 642 IYAVGGFDGNEFLNTVEVYNPQSNEWSPYTKIFQF
Figure 4.11. A, Pictogram of the primary amino-acid sequence of kelch related 
protein showing the approximate positions of the POZ/BTB domain and kelch 
repeats. B, amino-acid number position and composition of the kelch repeats, as 
identified using the blastp protocol.
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Mouse: 78 gccaaatttataaggaaaaatgattcccaatggatatttgatgtttgaagatgaaaattt 137
I I I I I I i I I I I I I  I I I I I I I I I I I I I I I i ! I I I I I I  I I I I I I I I I I I I M I N I  I I I I I
Human: 612 gccaaatttataaggaaaaatgattcccaatggatatttgatgtttgaggatgaaaattt 671 
Mouse: 138 tattgaatcatctgttgccaaattaaatgccttgaggaagagtgggcagttctgtgatgt 197
M I N I  I I  l l l l l l l l l l l l l l l l l l l l l  l l l l l l l  M i l l  l l l l l l l l l l l l l l
Human: 672 tattgagtcttctgttgccaaattaaatgccctgaggaaaagtggccagttctgtgatgt 731 
Mouse: 198 tcgacttcaggtctgtggccatgagatgctagcacacagggcagtcctggcttgctgtac 257
I I I I I I I I I I I  I I I I I I I I I I I I I  I I I  l l l l l l l l l l  M i l l  I I  I I I  I I I  I I I
Human: 732 tcgacttcaggtctgtggccatgaaatgttagcacacagagcagtgctagcttgctgcag 791 
Mouse: 258 gccctatctatttgaaatcttcaatagtgacagtgaccctcatggagtttctcatgtgaa 317
l l l l l l  1 1 1 1 1 1 1 1 1 1 1 1 1  1 1 1 I I 1 1 1  M i l l  1 1 1 1 1 1 1 1 1  l l l l l l l  I I  I I
Human: 792 tccctatttatttgaaatctttaatagtgatagtgatcctcatggaatttctcacgttaa 851 
Mouse: 318 gttggatgatctcaatccagaagctgttgaagtcttgctgaattacgcatacacggctca 377
I I  1 1 I I 1 1 1 1 1 1 1 1 1 1 I I 1 1 1 1 1 1 1 1 1 I I 1 1 1 1 1 1  l l l l l l l  I I  M i l l  M i l l
Human: 852 atttgatgatctcaatccagaagctgttgaagtcttgttgaattatgcctacactgctca 911 
Mouse: 378 gttgaaagctgataaggaattagtaaaagatgttaattctgcagccaaaaagctgaagat 437
I I  I I  I I  I I I I I I I I I I I  I I I I I I I I I I I I I I I l l l l l l l l l l  l l l l l l l l l l l l l l
Human: 912 gttgaaagcagataaggaattggtaaaagatgtttattctgcagcaaaaaagctgaagat 971 
Mouse: 438 ggacccagtcaagcaggtctgcggagattatttactatctagaatggatgttactagctg 497
I I I  I I I I  1 1 1 1 1 1 I I  I I  I I  1 1 1 I I 1 1 1 1 I I  1 1 1 1 1 1 1 1 1 1 1 1 1 I I 1 1  M i l l
Human: 972 ggatcgagtaaagcaggtttgtggtgattatttactgtctagaatggatgttaccagctg 1031 
Mouse: 498 catctcttaccgaaattttgcaagttgtatgggagactcccgtttgttgaataaagttga 557
I I i I I I I  I I I I I I I I I I I I I I I I I I  I I I I I I I  I I I I I I I I I I  I I I I  I I  I I I  I I  I M i l l
Human: 1032 catctcttaccgaaattttgcaagttgtatgggagactcccgtttgttgaataaggttga 1091 
Mouse: 558 cgcttatattcaggagcatttgttacaaatttcagaagaggaggaatttcttaagcttcc 617
II I II I I II II I I I I I I I I II II I I I I I I I I I II I I I I I I II I l l l l l l l l l l l l l l
Human: 1092 tgcttatattcaggagcatttgttacaaatttctgaagaggaggagtttcttaagcttcc 1151 
Mouse: 618 gagactaaagttggaggtaatgcttgaagataatgtgtgcttgcccagcaatggcaagtt 677
II I II I I I I I I I I I I II I I I I I I I I I I I I I II I I I I I I I I I I I I I I II I I I I I I II
Human: 1152 aaggctaaagttggaggtaatgcttgaagataatgtttgcttgcccagcaatggcaaatt 1211 
Mouse: 678 gtatacaaaggtaatcaactgggtgcagcgtagcatctgggagaatggagacagcctgga 737
I I I I I  I I I  I I I I I I  I I I I I I I I I I I I I I I I I I I I I I I I I I I  I I I I I I I I I I I I M i l l
Human: 1212 atatacaaaggtaatcaactgggtgcagcgtagcatctgggagaatggagacagtctgga 1271
93
797
1331
857
1391
917
1451
977
1511
1037
1571
1097
1631
1157
1691
1217
1751
1277
1811
1337
1871
1397
1931
738 ggagctcatggaagaggttcaaaccttgtactactcagetgatcacaagctgcttgatgg
M i l l  l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
1272 agagctgatggaagaggttcaaaccttgtactactcagetgatcacaagctgcttgatgg
7 98 gaacccactagatggacaggctgaggtgtttggcagtgatgatgaccacattcagtttgt
M i l l  I I < I I 1 1  I I M  I I  M  M  I I  1 1  M  I !  M  I 1 1  M  M  I I I M  M  I I 1 1 1  I M  i 1 1  I I
1332 gaacctactagatggacaggctgaggtgtttggcagtgatgatgaccacattcagtttgt
858 gcagaaaaagccaccccgtgagaatggccataagcagataagtggcagttccactggatg
l l l l l l l l l l l l l l l  I I I I  I I I I I I I I I I  I I I I I I I I I I I I I l l l l l l l  l l l l l l l l
1392 gcagaaaaagccaccacgtgagaatggccataagcagataagtagcagttcaactggatg
918 tctctcttctccaaatgcttcaatgcaaagccctaagcatgagtggaaaatcgttgcttc
l l l l l l l l l l l l l l l l l l l  II I l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
1452 tctctcttctccaaatgctacagtacaaagccctaagcatgagtggaaaatcgttgcttc
97 8 agaaaagacttcaaataacacttacttgtgcctggctgtgctggacagtacattctgtgt
I M l  M l  M l  M l  I I I I I I I  M  I I M I M M  I I I  1 1 !  1 1  I I I  I I I I I  l l l l l l l l !
1512 agaaaagacttcaaataacacttacttgtgcctggctgtgctggatggtatattctgtgt 
1038 cattttccttcatgggcggaacagtccacagagctcaccaacaagtactccaaaactgag
M I N I  1 1 1 1 1 1 1 1 1  I M i l l  1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1  I I
1572 catttttcttcatgggagaaacagcccacagagctcaccaacaagtactccaaaactaag 
109 8 caagagtttaagcttcgagatgcaaccagatgagettctagaaaagcccatgtcteecat
l l l l l l l l l l l l l l  l l l l l l l l l l  I I  I I  I I I I I I I I I I I I I I I I I I I I  I I I I I
163 2 taagagtttaagctttgagatgcaacaagatgagctaatcgaaaagcccatgtctcctat 
1158 gcagtacgcacggtctggactagggacagcagagatgaatggcaaacteatagetgcagg
I I I I I  I I  I I  I I I  M i l l  I I  I I  I I I I I I  I I I  I I I I I I  I I I I  I I  I I  I I I I  I I I I I I I I
1692 gcagtacgcacgatctggtctgggaacagcagagatgaatggcaaactcatagctgcagg 
1218 tggttataacagagaggaatgtcttcgaacagttgaatgctatgatccacatacagatca
I I I  I I I I I I I  I I I I I I I I I I I I I I I I I I I I I I I I  I I I I I I I  I I I I  I I I I I I  I I I I I I
1752 tggctataacagagaggaatgtcttcgaacagtcgaatgctataatccacatacagatca
1278 ctggtccttccttgctcccatgagaacaccaagagcccgctttcaaatggctgtgctgat
I I 1 1 1 1 1 1 1  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 I I 1 1 1 1  I I M I I I M I M M  I !  I I
1812 ctggtcctttcttgctcccatgagaacaccaagagcccgatttcaaatggctgtactcat
13 3 8 gggacagctctatgtggtgggtggatcaaatggacactcagatgacctgagttgtggaga
I I I  I I M I I I M I M M  l l l l l l l l l l l l l l  1 1 1 I I 1 1 1 I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1872 gggccagctctatgtggtaggtggatcaaatggccactcagatgacctgagttgtggaga
94
Mouse: 1398 aatgtatgatccaaacattgatgactggacccctgttccagagctgagaaccaaccgttg 1457
M I N I M I  l l l l l l l  1 1 1 1 1 1 1 1 1 1  I I I 1 1 1 1 1 1 1 1  l l l l l l l  l l l l l l l l
Human: 1932 gatgtatgattcaaacatagatgactggattcctgttccagaattgagaactaaccgttg 1991
Mouse: 1458 taatgcaggagtgtgtgctctgaatgggaaattgtacattgttggtggctctgatccata 1517
I I I I I I  I I I I I I I  I I I I I  I I  I I I  I I I I I I  I I  M i l l  I I I I I I I I  I I I I I I I I I I I  I
Human: 1992 taatgcaggagtgtgtgctctgaatggaaagttatacatcgttggtggctctgatccata 2051
Mouse: 1518 tggtcaaaagggcctgaaaaattgtgatgtatttgatcctgtaacgaagtcatggacaag 1577
I I I I I I I I I I I  I I I I I I I I I I I  I I I I  I I I I I I I I I I I I I I I I I 1 1 1 1  l l l l l l l l
Human: 2052 tggtcaaaaaggactgaaaaattgtgatgtatttgatcctgtaacaaagttgtggacaag 2111 
Mouse: 1578 ctgtgctcctcttaacattcgtcgacaccagtctgcagtttgtgaacttggtggttattt 1637
I I I  I I I l l l l l l l l l l l l l l  I I I I I I I I I I I I I I I I M i l l  I I I I I I I I I I I I I I
Human: 2112 ctgtgcccctcttaacattcggagacaccagtctgcagtctgtgagcttggtggttattt 2171 
Mouse: 1638 gtatataattgaaggtgcagaatcttggaattgtctgaacacagtagaacgatacaatcc 1697
I I I  M i l l  I 1 1 1 1 1 1 1 1 1 1 I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I 1 1 1 1 1 1 1 I I I I 1 1 1 1 1 I I 1 1
Human: 2172 gtacataatcggaggtgcagaatcttggaattgtctgaacacagtagaacgatacaatcc 2231 
Mouse: 1698 tgaaaacaacacctggactttaattgcacccatgaatgtggcgaggcgaggggctggagt 1757
I I  I I  I I  I I  I I I I I I I I I I I I I I I I I I I  I I I I I I I I I I I I I l l l l l l l l  l l l l l l l l
Human: 2232 tgaaaataatacctggactttaattgcacccatgaatgtggctaggcgaggagctggagt 2291 
Mouse: 1758 cgctgtgcttgatggaaaactgtttgtaggtggtggctttgatggttctcacgccatcag 1817
M i l l  I I I  1 1 1 1 1 1 1 1 1 I I I I 1 1 I I  M I I I I I I I I I I I I I M M M I  l l l l l l l l
Human: 2292 ggctgttcttaatggaaaactgtttgtatgtggtggctttgatggttctcatgccatcag 2351 
Mouse: 1818 ttgtgtggagatgtatgatccaactagaaatgaatggaagatgatgggaaatatgacttc 1877
I I  I I  I I I I I  I I I I I I I I I I  I I I I I I  I I I I I I I I I I I I I I I I I I  I I I I I  I I  I I I I I I I I I
Human: 2352 ttgtgtggaaatgtatgatccaactagaaatgaatggaagatgatgggaaatatgacttc 2411 
Mouse: 187 8 accaaggagcaatgctgggatcacaactgtagggaataccatttatgcagtgggaggatt 1937
I I II I I I I I II I I I I I I I I I I I I I I I I I I I I II I I II I II I I II I I I II I I II I I I I
Human: 2412 accaaggagcaatgctgggattgcaactgtagggaacaccatttatgcagtgggaggatt 2471 
Mouse: 1938 cgatggcaatgagtttctgaatactgtggaagtctacaaccctcagtcaaatgagtggag 1997
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 1 1 1 1  I l l l l l l l l l l  M i l l
Human: 2472 cgatggcaatgaatttctgaatacggtggaagtctataaccttgagtcaaatgaatggag 2531 
Mouse: 1998 cccttacacaaagattttccagttttaacaaatttaagaac--cccaaactaacaggctt 2055
I I I  I I  I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
Human: 2532 cccctatacaaagattttccagttttaacaaatttaagaccctctcaaactaacaggctt 2591
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Mouse: 2056 agtgatgtaattgtcgtttagtagaggt-cacttgtgaataaggagggtgggtggggtaa 2114
I I I I I I I I I I I ! I I I I M  M  I I  I I  I I  I I I I I I I I I I I I I I I I I  I I I I I I I I I I
Human: 2592 agtgatgtaattgt-ggttagtagaggtacacttgtgaataaagagggtgggtgggtata 2650 
Mouse: 2115 gatgttgctaacctgcaacaccaagcttttgcatattgcttattattaaacatgctggcc 2174
l l l l l l l l l l l  I M I N I !  M M M  l ;  I M l  I I  I N  I I  l l l l l l l l l l l l l l  I
Human: 2651 gatgttgctaa-cagcaacacaaagcttttgcatattgcatactattaaacatgctgtac 2709 
Mouse: 2175 atactttttggg gttggaatggaatgcaaagatgaa 2210
M I N I M U M  M M M  I I I I I 1 1 1 1 I I 1 1 I I I
Human: 2710 atactttttgggtttatttggaaaggaatgcaaagatgaa 2749
Figure 4.12. Demonstration of homology between mouse and human novel kelch cDNA 
sequences. Start and stop codons are highlighted in red.
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Figure 4.13. Example of SSCP analysis o fcD N A s corresponding to mouse kelch- 
related gene. A, 250b segment from the 5 ’ end. B, 2(K)b segment from the centre 
portion of the gene. Lanes are marked 1-12, corresponding to the following cell 
lines: 1, C5N; 2, C50; 3, MSCP1; 4, B9; 5, A5; 6, D3; 7, CarB; X, CarC; 9, 
S N 161; 10, E4; 11, HI 1; 12,PDV
gene cloned in our laboratory is shown in figure 4.12. Again a high degree of 
homology was evident between man and mouse: 93% overall homology at the DNA 
level and 94% at the protein level.
Again, mutations were looked for in the cloned gene in mouse cell lines using SSCP. 
Examples of the SSCP gels are shown in figure 4.13. No sequence variations and 
therefore mutations were evident
4.4 Novel Member of l(2)gl Gene Family
The third gene examined was a novel member of the lethal in giant larvae (l(2)gl) 
gene family. This gene is known to be a tumour suppressor in Drosophila, where it 
was first characterised (Strand et a l, 1994). It was isolated from the human 
senescent fibroblast library. Its chromosomal position was not known. However, 
given its known role in embryogenesis and its tumour suppressor function in 
Drosophila, it was thought worthy of further study.
A 900bp human probe was used directly to probe the mouse cDNA library. The 
corresponding positive primary and secondary lifts are shown in figure 4.14. Despite 
a total of eight clones being isolated, I was unable to find any that were 
representative of the 3’ and of the gene. I therefore designed forward primers from 
the 3’most sequence to be used in combination with the KS primer of the vector, 
yielding a ~600bp probe. This too failed to identify any clones representing the 3’ 
end of the gene. Primers designed directly from the 3’ region of the known human 
sequence were not helpful. I was therefore unable to clone the entire coding region 
of the novel 1(2)gl gene. The obtained sequence is shown in figure 4.15.
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Figure 4.14. Autoradiographs of primary (A) and secondary (B) 
filters corresponding to mouse l(2)gl clones.
20
30
80
90
140
150
200
210
259
269
319
329
379
389
439
449
499
509
559
569
619
629
ggacggcctgaccgcaggctcgtcctcggcctcgcaacagcagcaacagcagcagcaccc 79
i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
ggacggcctgaccgcaggctcgtcctcggcctcgcaacagcagcaacagcagcagcaccc 89
gcctgggaaccgggagccggagatccaggagacgctccagtccgaacacttycaactctg 139
1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I 1 1  l l l l l l l l l l l l l l l l l l l l l l l l l l  M i l l  l l l l l l l l
gcctgggaaccgggagcccgagatccaggagacgctccagtccgagcacttccaactctg 149
caagactgttcgccatggattcccctatcagccctcagccctggcctttgatcccgttca 199
11111111111111M11111 I I1111M111111111111111111111111111111
caagactgttcgccatggatttccctatcagccctcagccctggcctttgatcccgttca 209
gaagatcctggcggtaggaatccagactcggtgctttaaggctctttggtcgtccaggag 258
i i i i i i i i i i i i i i i i i i i i  l l l l l l l  M  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I 1 1 1 1 1 1 1  I
gaagatcctggcggtaggaacccagact-ggtgctttaaggctctttggtcgtccagggg 268
tggaatgttattgccagcacgacagcggagcagcagtgatccaactccagttcctgatta 318
1 1 I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1  l l l l l l l l  i i i i i i i i i i i i i i i i i i i
tggaatgttattgccagcacgacagcggagcggcagtgattcaactccagttcctgatta 328 
atgagggagcccttgtgagtgccttggctgatgacaccctacacttatggaatttacgtc 378
M 1 1 1 1 1 1 1 1 1 1 M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 M 1 1 1 M I  l l l l l l l  i i i i i i i i i i i i i
atgagggagcccttgtgagtgccttggctgatgacaccttacacttgtggaatttacgtc 388 
aaaaaaggcctgccgtactacattcacttaaattttgcagagaaagggttacattttgcc 438
I I I I I I I I I I I I  I I  l l l l l l l l l l l  I I I  I I  I N I  I I I  I I I  I I I  I I I I I I I I I 1 1 1 1
agaaaaggcctgctgtgctacattcactcaaattttgcagagaaagggttacattttgcc 448 
atctgcctttccagagtaagtggctctatgtgggcactgagcgaggaaacatacacattg 498
M M M M M M M M M M M M M M M M M M I  M  M  M  I M  M  M  I M M
atctgcctttccagagtaagtggctctatgtgggcacggaacgaggtaatatacatattg 508 
ataatgtggagtccttcacactctcaggctatgtcattatgtggaataaagccatcgaac 558
M M M M M M M M M M M M M M I  M M M M M M M M M M M M M M
tcaatgtggagtccttcacactctcaggctacgtcattatgtggaataaagccatcgaac 568 
tgtcatctaaagctcacccaggaccagttgtgcatataagtgacaatcccatggacgagg 618
M M M M M I  M M I M I M M I  M  M I  M M M M M I  M M M M M M M M
tgtcatctaaatctcacccaggacctgttgtccatataagtgataatcccatggacgagg 628 
ggaagcttttgattggcttcgaatctggaacagtagtcttatgggacctcaagtcaaaga 678
M M M M  M M M M M  M M M M M M M M M M M M M M I  l l l l l l l l l l
ggaagcttctgattggctttgaatctggaacagtagtcttatgggaccttaagtcaaaga 688
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Mouse: 679 aggctgactacagatacacatacgacgaggctattcactctgtggcttggcatcatgaag 738
l l l l l l l l l l l l l l l l l l l  M I N I M I  j l M I M M M M M M M I I M I I I M I I
Rat : 689 aggctgactacagatacacttacgacgaggctattcactctgtggcttggcatcatgaag 748 
Mouse: 739 gaaaacaatttatttgcagtcattctgacggtactttgaccatatggaatgtgagatccc 798
i i i i i i i  i i i i i i i i i i i i i i i i i i i i  m u  m m i M M i i i m i i i  m i
Rat : 749 gaaaacagtttatttgcagtcattctgatggtacattgaccatatggaatgtgaggtccc 808 
Mouse: 799 ctgctaaacctgtacagaccatcactcctcacggaaaacagttgaaggatgggaagaagc 858
ii M i M M M i M M i M M M i m i i i M i M M i i m  l l l l l l l l l l l l l l  i
Rat : 809 ctactaaacctgtacagaccatcactcctcacggaaaacagttaaaggatgggaagaaac 868 
Mouse: 859 cagagccatgcaagcctatcctgaaggtggagttgaagacaacaagatccggggaacctt 918
i m u  m m m m i i  i m i i i i i  m i m i m i i m m  i i i i i i i n i
Rat : 869 ccgagccgtgcaagcctatcctcaaggtggagttcaagacaacaagatcgggggaacctt 928 
Mouse: 919 ttattattttgtcaggaggcttatcctatgataccgtgggaagaaggcactgcttaacag 978
i i i i i i i i i i i i i  i i i i i i i i i  i i i i i i i i i i i i i i i i i i i i  i i m m m
Rat : 929 ttattattttgtcgggaggcttatcatatgataccgtgggaagaagaccttgcttaacag 988 
Mouse: 979 tgatgcacgggaaaagcacagcagtgctggaaatggactattcaatcgttgactttctcal038
i i i i i i i  i i i i i i i i i i i  m m m m m m m m i i  n m i m m
Rat : 989 tgatgcatgggaaaagcacggcagtgctggaaatggactattcaattgtcgactttctcal048 
Mouse: 1039 cactctgtgaaacgccatatccaaacgattttcaaggaaccatatgctgtggttgttcttl098
m m m m m m m m i  i i i i i i i  i i i i  i i m m m m i i i m m i  i
Rat : 1049 cactctgtgaaacgccatatccaaatgattttc-aggagccgtatgctgtggttgttc-tl106 
Mouse: 1099 cctggaaaaggacttagtgctgatagaccttgcacaaaatggataccctatatttgagaal158
l l l l l l  M  M  I M M M M M M M M I  M i l l  I I I I I I I I I I I I I I I I I I I I 1 1 1
Rat : 1107 cctggagaaggatttagtgctgatagacctggcacagaatggataccctatatttgagaall66 
Mouse: 1159 t-cctacccttttgagtatccacgaagtccctgttccatgtttgggaatattttgcttgtl217
i i i i i i i i  i i i i i i i i i  m u  i i i i i i i  i i i i  m  m i i i i m i i  i
Rat : 1167 tccctaccc-tttgagtatacacgagtcccctgttacatg-ttgtgaatattttgctgatl224 
Mouse: 1218 tgtcctg 1224
MMMI
Rat : 1225 tgtcctg 1231
Figure 4.15. Demonstration of cDNA sequence homology between the 5 ’ end of the 
cloned l(2)gl related gene and rat tomosyn
101
CHAPTER 5 
DISCUSSION
102
5. Discussion
Based on my observations, there is a moderate frequency of loss of heterozygosity on 
the acromeric region of mouse chromosome 6 in the two stage skin carcinogenesis 
model. The highest frequency of loss (33%) is seen at marker D6Mit236, situated 3.1cM 
from the acromere and corresponding cytogenetically to band A2. The data are 
suggestive, particularly from analysis of the Spretus x NIH and Senear x Balb tumours, 
that loss of this marker and the region between D5mit83 and D6mit50 represents a 
smallest common deleted region (SCDR), implying the presence of a tumour suppressor 
gene.
The significance of loss of heterozygosity data is however sometimes difficult to judge, 
and should be seen at most as suggestive of the presence of novel tumour suppressor 
genes. Certainly it should be borne in mind that there is an expected background level of 
LOH in sporadic tumours, consistent with general genetic instability, and not necessarily 
implying the presence of a TSG. Conventional wisdom is that a background frequency 
of 10% is to be expected, and that a frequency of over 20% is significant. Relative to 
this, a rate of 33% at the D6Mit236 locus in a series of 55 tumour cases is likely to be of 
significance. It may be however that particular parts of the mouse genome are prone to 
greater instability than others. This is known to be the case in humans. In particular, the 
7q31 region is recognised as harbouring a recombinational hotspot as well as an 
aphidicolin -inducible fragile site, identified during attempts to clone the cystic fibrosis 
gene (Karem et al., 1989; Huang et al., 1998a, b). This may provide an alternative 
explanation of the high frequency LOH in the region, viz., intrinsic genomic instability 
rather than targeted inactivation of a TSG. Recent work however suggests otherwise: 
introduction of chromosome 7 into a highly aggressive prostate carcinoma cell line 
resulted in increased tumour latency by at least twofold, with introduction of 
chromosome 12 having no effect (Zenklusen et al., 2000). This does lend weight to the 
argument that chromosome 7 harbours a TSG.
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The large discrepancy between the frequency of LOH in my studies and that in 
published series (Zenklusen et al., 1996b, 1997), even when using the same markers, 
may be explained in a number of ways. Firstly, in deciding to score for LOH only those 
tumours with unequivocal allele loss as determined by visual examination, I may have 
underestimated the true frequency. I chose this line of action in order to minimise false 
positive results from contaminating stromal tissue. Secondly, the strains of mice used to 
create FI hybrids in my experiments are different from those chosen by Zenklusen in his 
investigations, and would have different genetic backgrounds that might influence 
genetic changes during tumorigenesis. It is certainly recognised that strains of mice 
differ in their propensity to develop tumours secondary to carcinogen exposure, a 
phenomenon that undoubtedly has a genetic cause. Clearly also the grade or stage of 
tumours may have been different between the two studies. Lastly, it is worth mentioning 
that the number of tumour cases examined by Zenklusen and coworkers was 
considerably smaller than that examined here. Small series may well overestimate the 
frequency of losses.
This is the third report of consistent LOH on mouse chromosome 6A2 in tumours 
induced by chemical carcinogenesis. Zenklusen and colleagues have reported high 
frequencies of allele loss in tumours derived from mouse skin and also rat liver, another 
well defined chemical carcinogenesis protocol ((Zenklusen et al., 1996b, 1997). In 
addition, several sources have confirmed consistent LOH in a variety of human 
epithelial cancers at 7q31, the region syntenic to mouse 6A2. Allele loss distal to the met 
oncogene at 7q31-33 is reported to be as high as 81% in breast cancer (Zenklusen et al., 
1994b). These same authors found a similar order of loss (73%) in ovarian tumours at 
the same locus DS522 (Zenklusen et al., 1995), confirming earlier reports (Cliby et al., 
1993). Allelotyping data from SCC of the head and neck (Nawroz et al., 1994) again 
suggest that LOH in this region is common in this tumour type (30-50%). Lastly, in 
colon and prostate cancers, LOH on chromosome 7 at frequencies in excess of 80% 
have been documented (Zenklusen et al., 1995b; Zenklusen et al., 1994). These 
molecular studies confirm earlier cytogenetic observations of common deletions in the 
long arm of chromosome 7 (reviewed in Zenklusen and Conti, 1996). Together, these
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data argue for the presence of a novel TSG at these loci which is conserved across 
species. Functional studies have added to the strength of this argument. Tumorigenicity 
can be repressed by the introduction of human chromosome 7 into a murine carcinoma 
cell line (CH72) using microcell mediated transfer techniques, an effect specific to 
chromosome 7 since introduction of chromosome 15 has no discernible effect 
(Zenklusen et al., 1994a). Interestingly, two of the seven microcell fusion clones 
obtained from these experiments were at least as aggressive as the original CH72 cell 
line. One of these clones was shown on allelotyping to lack markers in the 7q31 region, 
implying a deletion. These observations are entirely consistent with previous findings of 
LOH at this locus in solid tumours.
Using somatic cell genetics, this work has been taken further in our laboratory. 
Systematic deletion mapping has been undertaken of immortal segregants arising from 
human fibroblast/chromosome 7 fusion clones. These segregants (or revertants) are 
clones that, having lost the immortal phenotype subsequent to introduction of 
chromosome 7, then revert to the original phenotype as a consequence of loss of genetic 
material. Although losses occurred at three loci spanning 10 Mb (D7S522, D7S821 and 
D7S633-17TA-5/17B-RE3), one of these coincided almost exactly with solid tumour 
LOH studies. A recent analysis of 7q loss in ovarian cancer undertaken by a collaborator 
at Queen’s University, Belfast found the highest loss at marker 17TA-5/17B-RE3, in 
agreement with our studies (H. Russell, unpublished). Interestingly, several tumours 
were found to have partial deletions spanning CFTR and the region just proximal to this 
(A Hurlstone, PhD Thesis). The highest losses found in my experiments in mouse 
occurred at marker D6Mit236, contained within an intron of mouse cftr. Further, the 
deletion found in one of the two revertants in Zenklusen’s mouse cell/chromosome 7 
fusion experiments discussed above was located at the cftr locus.
Attempts to define further a SCDR might take the form of large scale tumorigenesis 
studies with deletion analysis of mouse carcinoma/chromosome 7 derived tumours 
whose growth kinetics have reverted to wild type, implying inactivation of a TSG on 
chromosome 7. The introduction of fragments of chromosome 7, and indeed the
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smallest possible region required to induce tumour suppression, might facilitate 
mapping efforts. Employment of the RDA technique might be an applicable strategy, 
particularly in the analysis of possible microdeletions in those segregants with no 
obvious allele loss.
The finding of aneuploidy in chemically induced papillomas, as well as carcinomas and 
spindle cell tumours, in chromosome painting studies supports the notion that this is an 
early event in the mouse skin system. This is likely to reflect general chromosomal 
instability, and may be due to an event that occurred during initiation or specifically to 
the action of the promotor. One should of course exercise caution in interpreting 
karyotype changes in cultured cell lines, since continuously passaged cells are doubtless 
in a state of genetic flux that may not reflect the situation in vivo. This is underlined by 
the chromosome painting analysis of C5N, a ‘normal’ keratinocyte line which 
karytypically is highly abnormal. However, these findings in vitro do seem to be borne 
out from both cytogenetic and molecular studies in vivo. Aldaz has suggested (Aldaz et 
al., 1996) that, following TPA treatment, an initiated population of cells undergoes 
random chromosomal alteration. Subsequently, clones of cells develop which harbour 
trisomies of chromosome 6 (and 7) as a result of the growth advantage imparted by 
them. The finding of LOH in papillomas at a rate as frequent as in carcinomas reinforces 
that these genetic changes are an early event in carcinogenesis.
Trisomy is not necessarily associated with tumour suppressor genes, and in many cases 
implies selection for abundance of a growth promoting gene product. This is likely to 
explain the selection for multiple copies of chromosome 7, where the mutant H-ras gene 
resides. The role played by H-ras in the initiation of mouse skin tumours has been 
firmly established. However, trisomy is also entirely compatible with TSG inactivation. 
For example, once a chromosome carrying a mutated TSG is duplicated (through non­
disjunction) to produce a trisomy, complete inactivation of the gene can occur by 
mitotic recombination with the defective chromatid, which is then detectable at the 
molecular level as LOH.
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Having found a significant level of LOH on mouse chromosome 6 A2 and defined, 
tentatively, a smallest common deleted region centred on marker D6mit236, the task of 
narrowing down on a potential TSG could take several forms. The known genes in the 
area should be screened for mutational inactivation in the panel of cell lines from the 
mouse carcinogenesis system, by examination for SSCP in cDNAs and exonic genomic 
DNA sequences. Examples of these genes would be wnt2, met and cappa2. Although 
there is no obvious biological explanation nor any prior evidence supporting the notion 
that cftr is a TSG, it should be included within the list of candidates. Assuming that the 
area will also harbour genes not yet discovered and sequenced, the area encompassing 
the SCDR would have to be spanned with clone contigs, and these sequences screened 
for genes. Again, the candidate genes identified would require to be examined for 
mutations. The recent publication of the first complete sequence of the human genome 
will provide further potential candidates. Indeed, positional cloning as previously 
understood will be more and more superseded by the positional candidate gene approach 
as a consequence of the human genome project. There are, of course, other methods of 
gene silencing than deletion or mutational activation of TSGs: loss of expression may 
result from mutation of transcription controlling elements, or from methylation changes 
(Merlo et al., 1995; Herman et al., 1995). These can be looked for by expression studies, 
and Southern blot analysis using methylation specific restriction enzymes. Once found, 
a good candidate gene would be expected to induce tumour suppression when 
introduced into a tumour cell line.
The candidate genes I cloned in the mouse system were chosen for their upregulation in 
a human senescent fibroblast library relative to non-senescent cells. Senescence 
describes the state of irreversible growth arrest reached by a cell after a finite number of 
doublings (eponymously termed the Hayflick number) (Hayflick, 1965). Although first 
described in in vitro studies of primary epithelial cultures, there is evidence that 
senescence pertains in vivo (thoroughly reviewed by Campisi, 1996). Induction of 
replicative senescence is thought to be one method of tumour suppression, by acting to 
limit the doubling potential of cells. Although loss of the senescent phenotype may not 
be crucial at the early stages of carcinogenesis, it may well be a requirement for the
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development of invasion and metastases. There is independent evidence in man that 
there exists a senescence gene on the long arm of chromosome 7 (Otaga et al., 1993). 
The exciting hypothesis being examined in our laboratory is that this gene is one and the 
same as the putative tumour suppressor gene at 7q31. Genes which are upregulated in 
senescing fibroblasts relative to pre-senescent cells, and which map to human 
chromosome 7, are therefore potential candidate tumour suppressor genes.
The first gene I examined, a putative cyclin G1 binding protein, had already been cloned 
in mouse, but the exercise allowed me to establish proof of principle and gain 
experience of the techniques involved. The gene is small and therefore recoverable in a 
single clone. Its putative function is based on observations that its protein product 
interacts with cyclin G1 in the yeast-2-hybrid system, an observation that may or may 
not hold true in vivo.
Arguably the most interesting gene examined was a novel kelch-related gene, again 
identified first in the human senescence library. This gene has not hitherto been cloned 
in mouse in its entirety. First identified in 1993 from a female sterile Drosophila mutant, 
kelch was shown to be a constituent of oocyte ring canal structures which permit 
cytoplasmic transport between the oocyte and nurse cells (Xue and Cooley, 1993). The 
repeating structural motif, now termed the kelch motif, first described in the Drosophila 
kelch ORF1 protein, comprises approximately 50 amino acids, is repeated three to six 
times and has been shown to interact with actin. The kelch motif in Drosophila is 
required for the correct localisation of the protein to ring canals.
The use of bioinformatics has shown that this motif is ancient and widely dispersed 
during evolution. It is present, for example, in the A55R and C2L ORFs of vaccinia 
virus, spe-26 of Caenorhabditis elegans (Varkey et al., 1995), the predicted IPP protein 
of mouse (Kim et al., 1999), a- and p-scruin of the Limulus crab (Way et al., 1995a,b) 
and the NRP/B and NS1 binding proteins in humans (Kim et al., 1998; Wolff et al.,
1998). Direct evidence of actin association has been demonstrated in a-scruin of 
Limulus as well as colocalisation of actin filaments with Drosophila kelch in oocyte ring
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canals. Fortuitously, the kelch repeat has also been identified in fungal galactose 
oxidase, for which the crystal structure has been solved (Ito et al., 1994). In this 
enzyme, the seven kelch motifs together form a conserved tertiary structure, the |3- 
propellor. Each kelch unit forms a four stranded (3-sheet, corresponding structurally to 
one blade of the propellor. The series of blades is arranged around a single axis. 
Although galactose oxidase is the only kelch related protein for which the crystal 
structure has been determined, the highly conserved primary sequence and theoretical 
predictions make it very likely that other members of this family also form (3-propellors.
A subset of the kelch family, which includes Drosophila kelch and my novel kelch 
related protein, can be defined by the presence of an additional motif, the POZ 
(Poxvirus and Zinc finger) domain, also known as the BTB (Broad complex Tramtrack 
and Brie a Brae) domain. This 120 amino acid motif is thought to permit homo- and 
heterodimerisation, and is particularly important in the group of zinc finger transcription 
factors. In the human promyelocytic leukaemia zinc finger (PLZF) protein, the POZ 
domain has transcriptional repressor activity and interacts with components of the 
histone deacetylase complex (Ahmad et al., 1998). The crystal structure of this protein 
has also been solved and shows a tightly intertwined dimer with an extensive 
hydrophobic interface (Ahmad et al., 1998). The amino acid sequence at the formed 
groove between the two protins appears to be highly conserved and is suggestive of a 
peptide binding site, for example with other nuclear proteins.
The physiological and biochemical functions of the known kelch family members, of 
which there are about twenty, remain largely to be determined. Despite sharing common 
structural features, their known functions seem to be quite diverse. Certainly their 
cellular localisation includes the nucleus, cytoplasm , cell surface and even extracellular 
(reviewed in Adams et al., 2000). Although the kelch repeat domain in a number of 
proteins is known to interact with actin, not all kelch containing proteins are actin 
binding molecules. Mayven (KLHL2), the human homlogue of Drosophila kelch, and 
IPP seem to be intimately involved in cytoskeletal modulation via actin association. 
Calicin, on the other hand, though still involved in cytoskeletal and organelle structure,
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is located in mammals in actin-negative structures termed calyces which are important 
in spermatocyte morphogenesis (von Bulow et al., 1995). The recently characterised 
NS1-BP (Wolff et al., 1998) is likely to have a role in mRNA splicing. This molecule 
was discovered by virtue of its interaction with a virally encoded protein, NS1. Upon 
infection with influenza virus, NS1-BP relocates throughout the nucleoplasm. Lastly, 
attractin, present in many mammals including man, is found extracellularly in serum and 
promotes monocyte spreading (Duke-Cohan et al., 1998).
Evidence that members of the kelch family may be involved in oncogenesis has come 
from a couple of sources. Recent cloning and molecular characterisation of KLHL3, a 
new human homologue of the Drosophila kelch gene, showed that it maps to human 
chromosome 5, corresponding to a smallest common deleted region in myeloid 
leukaemias (Lai et al., 2000). However, a search for inactivating mutations by SSCP in 
malignant myeloid cells was negative. In addition, recent evidence has suggested that 
overexpression of krpl, a novel rat kelch family member thought to be a transcriptional 
target of API, results in dramatically elongated pseudopodia in transformed rat 
fibroblasts, which may facilitate cell motility and invasion (Spence et al., 2000).
The novel kelch molecule cloned here has a single open reading frame of 1929 bp, 
resulting in a derived protein sequence of 642 amino acids and a predicted molecular 
weight of 71kDa. It contains both a POZ domain and a kelch repeat domain. The kelch 
motif is tandemly repeated six times, at amino acids 369 to 415, 416 to 463, 465 to 512, 
514 to 559, 560 to 606 and 608 to 642. From my experiments, there appeared to be no 
inactivating mutations in the series of cell lines representing various stages in the mouse 
carcinogenesis model. It is unlikely, based on these experiments, that kelch is a tumour 
suppressor gene involved in skin carcinogenesis.
Nevertheless much work remains to be done on this interesting molecule. Despite 
several attempts, I was unable to clone the novel mouse kelch from a genomic library. 
This needs to be achieved before the intron-exon boundaries can be identified. Patterns 
of expression need to be determined by Northern examination of tissue specific RNAs.
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In addition, chromosomal localisation should be sought using FISH or PCR of 
chromosome specific DNA. Expression of the protein in an expression system may 
allow antibodies to be raised to the molecule, which would allow cellular localisation 
studies by immunocytochemistry. Binding partners can also be sought, either by 
immunoprecipitation techniques or by employing the yeast-2-hybrid system. Going a 
stage further, and making full use of the mouse as model system, a knock out mouse 
could be constructed to explore further the role of this novel kelch.
The last gene cloned, albeit partially, in the mouse system was a novel homologue of the 
1(2)gl gene, first identified as a tumour suppresser in Drosophila. Over fifty genes have 
been described in Drosophila whose mutation produce tissue specific tumours, the best 
known of which is lethal (2) giant larvae (Strand et al., 1994a). Homozygous disruption 
of this locus results in malignant transformation of the neuroblasts of the presumptive 
adult optic centres in the larvae. The protein product has been shown to participate in a 
cytoskeletal network and undercoat the cell membrane in areas of cell-cell contact. 
Sequence comparisons with mammalian proteins show similarities with known 
mammalian junctional proteins. It is tempting to speculate that neoplastic transformation 
is a result of disruption of the cytoskeletal network.
Cloning of the mouse homologue of this gene confirmed the presence of related 
molecules in higher vertebrates (Tomotsune et al., 1993). Expression of mgl-1, the 
mouse homologue of Drosophila 1(2)gl, was found to be subordinate to Hox-C8, a 
mouse homeobox gene crucial to pattern formation in the embryo, and was found in 
highest abundance during embryogenesis in brain and spinal cord.
Despite numerous attempts, I was able only to clone the first 1200bp of the 5’ end of the 
cDNA. Interestingly, Jacob and colleagues state that in their attempts to clone the cDNA 
of the Drosophila gene, and despite extensively screening three cDNA libraries, they 
found only two cDNAs out of 32 characterised cDNAs (Jacob et al. 1987). This may be 
due to secondary structure in the mRNA precluding reverse transcription.
i l l
Unfortunately, while I was working on this novel 1(2)gl related gene, the rat sequence of 
tomosyn, a syntaxin-1 binding protein, was published which demonstrated very close 
homology to the 5 ’ sequence in my possession (Fujita et al. 1998). It is highly likely that 
I had cloned the mouse homologue of this new gene. Tomosyn (tomo (friend in 
Japanese) of syntaxin) forms a novel complex with syntaxin in nerve terminals and is 
probably one of the many components of the neurotransmitter release process. It is 
found specifically in the outer plexiform area of the retina and the post synapse of 
cerebellum. Presently, it is unclear how or whether this role as a likely synapse 
molecule, and its homology to a known Drosophila tumour suppressor gene, are related. 
It seems unlikely that it has a role in oncogenesis.
Our understanding of cancer has advanced dramatically since the discovery of 
oncogenes and tumour suppressor genes in the 1980s. This knowledge has permitted us 
to devise novel therapeutic approaches to the disease, based on a molecular 
understanding of the underlying cellular defects. Although drugs targeted at molecular 
pathways are currently few, the number is rising. Identification of new oncogenes and 
tumour suppressors clearly provides us with a broader range of targets which are 
expected to be more tumour specific and therefore less toxic. Arguably the most mature 
of the novel therapeutic approaches is targeting of the ras mitogen-activated protein 
kinase pathway. This strategy is particularly promising because the frequency of ras 
mutation is among the highest of any gene in human cancer (Bos, 1988; Kiaris and 
Spandidos, 1995). Ras proteins are among a small group of compounds undergoing a 
post-translational modification known as farnesylation, a process crucial to membrane 
binding and physiological function (Lerner et al., 1997; Sebti and Hamilton, 1997). 
Blockage of this process results in severe impairment of ras protein function. Farnesyl 
transferase inhibitors are remarkably specific and have been demonstrated to cause no 
gross systemic toxicity in animals. Dose limiting toxicities in humans when 
administered orally include myelosuppression, diarrhoea and lethargy (Eskens et al.,
1999). These compounds are currently in Phase I and II clinical trials. Interestingly, it is 
becoming increasingly clear that inhibition of ras farnesylation may not be the most 
important antitumour effect of this molecule. Activity does not seem to be dependent on
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ras mutation status, and recent evidence points to rhoB as a more likely target (Lebowitz 
and Prendergast, 1998). An alternative strategy to the inhibition of this pathway would 
be the use of an antisense oligonucleotide, also the subject of a Phase I trial (Gordon et 
a l, 1999).
The tumour suppressor gene p53 is also commonly mutated in human cancers, 
particularly at the time of relapse following therapy, and has been evaluated as a 
potential therapeutic target. Expression of wild type p53 can result in apoptosis in 
human cancer cells (Takahashi et al., 1992). Replacement of functional p53 using a 
variety of delivery systems (adenoviral, retroviral, liposomal) has been examined, both 
alone and in combination with standard cytotoxic chemotherapy (Wills et al., 1994; 
Fujiwara et al., 1994; Hupp et al., 2000). A particularly elegant approach has been to 
exploit the molecular difference between malignant and normal cells vis-'-vis p53 status. 
The best known of these is the ONYX015 adenovirus, which harbours an E1B deletion 
allowing replication and cytolysis only in p53 deficient cells (Biscoff et al., 1996), 
although recent work has questioned the molecular basis for this specificity (Rothmann 
et al., 1998). This concept has been explored in a variety of tumour types, including 
ovary (Vasey et al., 2000) and, more promisingly, head and neck (Khuri et al., 2000).
On the available evidence, the putative novel tumour suppressor, which formed the 
subject of this thesis, is inactivated in a very broad spectrum of solid tumours and at 
high frequency. This would imply an important and common role in tumorigenesis, and 
potentially a useful novel therapeutic target. The search for this putative multi-tissue 
tumour suppressor gene on the long arm of human chromosome 7, and the A2 region of 
mouse chromosome 6, should therefore continue.
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Table A l List of mouse ESTs used in designing PCR primers
Gene Mouse EST Accession
___________________________ Number_________________
Putative cyclin G l binding AA764288 
protein
Kelch AA109625
AA140498 
AA553216 
AA673812 
AA619726 
AA690294 
AA516929
1(2)gl homologue AA437465
Table A2 Description of probes used for Southern analysis
Probe Description
H-ras 300bp ECOR1 insert of BS9 (Ellis et al.,
1980)
Caveolin-1 700bp Smal fragment encompassing exon 1
Kelch 800bp product spanning central coding
homologue region and first kelch repeat
Table A3 List of PCR primers used for SSCP analysis 
of mouse putative cyclin G l binding protein
Primer Sequence___________________________
IF 5 ’TGCTCGGGACTCCGCCCTGGA3 ’
1R 5 ’TCCTCCAGCAAAACCTGGAAG3 ’
2F 5 ’ ACCACTTTAAACTTCGCTTC3 ’
2R 5 ’TCTGTCCTTTGTGAATGAGCT3 ’
129
Table A4 List of PCR primers used to amplify mouse 
kelch homologue
Primer Sequence
5F 5 ’ GCGTTCTCAGTGACACATTTC3 ’
5R 5 ’ CTTCTTGGCTGCAGAATAAACATC3 ’
6R 5 ’ CATTCTTTTAGATGTACGCTGC3 ’
IF 5 ’ GATCCAACTAGAAATGAATGGAAG3 ’
1R 5 ’ AGTTGGATCATACATCTCCACAC3 ’
2F 5 ’ CTAG AAAAGCCCATGTCTCCC3 ’
2R 5 ’ AGTTGGATCATACATCTCCACAC3 ’
3F 5 ’ GATGCAACCAGATGAGCTTCTAG3 ’
3R 5 ’TCTCGAAGCTTAAACTCTTGCTC3 ’
4F 5 ’ GTTACAAATTTCAGAAGAGGAGGA3 ’
4R 5 ’ CC ATTAAATCATCATCGCTCTC3 ’
7F 5 ’ GCTATGATCCACATACAGATCAC3 ’
7R 5 ’ CATCACTAAGCCTGTTAGTTT3 ’
Table A5 List of PCR primers used to amplify mouse 
l(2)gl homologue
Primer Sequence
IF 5 ’TCCGAACACTTCCAACTCTGC3 ’
1R 5 ’ CTTTGACTTGAGGTCCCATAAG3 ’
2F 5 ’ ACCCTCAGTTCTCCGTTC3 ’
2R 5 ’TACTGCACCTCAGCACC3 ’
3F 5 ’ AAGCTTTTGATTGGCTTCGAATC3’
4F 5 ’ AGTTATTGCAGAAGCGTCCCAG3 ’
4F 5 ’TAATTTGTCAGGCTTATCC3 ’
Table A6 Primers used in sequencing
Primer Sequence
KS TCGAGGTCGACGGTATC
SK CGCTCTAGAACTAGTGGATC
T7 GTAATACGACTCACTATAGGGC
T3 AATTAACCCTCACTAAAGGG
130
